InMed Pharmaceuticals, Inc. (IMLFF)

Our latest clients all have the potential to grow significantly in the near and long-term future

Re: InMed Pharmaceuticals, Inc. (IMLFF)

Postby QualityStocks » Wed Oct 25, 2017 5:08 pm

Biotechs Develop Proprietary Systems to Drive CBD Research and Development

NetworkNewsWire Editorial Coverage: The cannabinoid-based pharmaceutical market is rapidly expanding, driving increased demand for a reliable flow of high-purity cannabinoids. With a market that’s expected to grow from $2 billion in 2020 to $50 billion in only nine years, according to Statista (http://nnw.fm/3Uta4), biotechnology companies are increasingly focused on the development of proprietary systems and procedures to drive research and production of cannabinoid pharmaceuticals. One of the leading companies in this sector is InMed Pharmaceuticals, Inc. (CSE: IN) (OTCQB: IMLFF) (IMLFF Profile), which has created proprietary systems for bioinformatics and biosynthesis manufacturing of pharmaceutical-grade cannabinoids. Axim Biotechnologies, Inc. (OTCQB: AXIM) is taking a broader approach as the creator of innovative systems for the research, development and manufacture of new products in the pharmaceutical, nutraceuticals, phytoplant and botanical fields. These companies rely on bioinformatics tools to identify cannabinoids for medical applications; another industry participant in this regard is Cannabics Pharmaceuticals, Inc. (OTCQB: CNBX), which focuses on the development of personalized diagnostic and bioinformatics tools. Aphria, Inc. (TSX: APH) (OTCQB: APHQF), on the other hand, leverages the capabilities of its proprietary systems to produce agriculturally grown medical cannabis. Primarily focused on the development of modified and reduced-risk tobacco products aimed at reducing the harm caused by smoking, 22nd Century Group, Inc. (NYSE: XXII) is also gaining ground in the cannabinoid market by successfully creating industrial hemp plants that contain zero tetrahydrocannabinol (THC).

These are just some of the biotechs that have recognized the benefits of creating proprietary systems for new product development. These systems provide them with increased control over outcomes in their drive to create product of consistently high purity. This is critical in the emerging cannabinoid drug sector, where the Food and Drug Administration (FDA) has major concerns regarding the consistency of drugs and products manufactured from agricultural cannabis. Any biotech in this sector striving for approval from the FDA must ensure that its products are able to survive rigorous pharmaceutical testing and manufacturing standards.

InMed Pharmaceuticals (CSE: IN) (OTCQB: IMLFF) is the standout company in the field of pharmaceutical-grade cannabinoid biosynthesis. By using its proprietary systems and methods, InMed has developed the first bio-identical cannabinoid that has undergone formulation and preclinical testing. InMed will use its proprietary systems to develop other cannabinoid-based drugs, leveraging its technology to ensure enhanced consistency in production, purity, quality and structural integrity, all of which greatly increase the likelihood of gaining FDA approval for its candidates.

Using computer-based algorithms and proprietary bioinformatics to identify active cannabinoid combinations for the treatment of several diseases in dermatology, ocular disease, pain and other conditions, the company has the capability to advance drug candidates through formulation, preclinical and clinical testing.

InMed’s biosynthesis platform has several other advantages over agriculture-based production methods, including extensive cost savings resulting from not having to contend with the grow-harvest-extract-purify cycle necessary when using cannabis crops. Additionally, InMed’s biosynthesis process can produce all of the 90+ cannabinoids naturally found in cannabis, enabling the company to avoid the harmful chemicals that are used in the cannabis growing process and offering an easier way to scale-up from the laboratory to full production.

The company’s preclinical development pipeline includes INM-750 for the treatment of epidermolysis bullosa (EB), an orphan pediatric disease with no currently approved therapy. The potential global market revenues for this drug are estimated at $1 billion. INM-085, a second drug in development, is being studied as a treatment option for glaucoma, with its global market value of over $5 billion. More than three million Americans are estimated to be living with glaucoma, and over 120,000 have been blinded by this condition (http://nnw.fm/Of680).

The company has streamlined its proprietary systems, enabling it to create bio-identical cannabinoids in the controlled setting of a laboratory, and it is currently working on scaling up its manufacturing capability. Once at commercial scale, the company will be uniquely positioned to maximize its potential by assisting other companies with cannabinoid-based drug development programs. The company recently filed a provisional patent for biosynthesis of cannabinoids. Once converted into an International Patent Cooperation Treaty (PCT) application, InMed will look to pursue key jurisdictions on an international scale (http://nnw.fm/WJ8zY).

Another company that is actively engaged in cannabinoid research and development is Axim Biotechnologies (OTCQB: AXIM). Based in the Netherlands, the company is conducting research into a patented cannabinoid delivery system to treat multiple sclerosis (MS) patients suffering from pain and spasticity. Axim’s research and testing is conducted in compliance with the strict guidelines of the FDA and European Medicines Agency (EMA). In a recent development, on October 5, 2017, Axim was granted a patent for a cannabinoid ophthalmic solution developed for the treatment of glaucoma and conjunctivitis.

Cannabics Pharmaceuticals (OTCQB: CNBX) provides diagnostic tools and bioinformatics to support practitioners and patients. Also engaged in scientific and clinical research through its subsidiary, Grin Ultra, the company is developing cannabinoid-based medicine for cancer patients, examining efficacy through in-vitro studies and clinical trials. Cannabics is currently studying the effect of its proprietary cannabis capsules on weight and appetite loss in cancer patients. The company recently filed national phase patent applications for its proprietary cannabis-based cancer cell screening technology in the United States, Canada, Europe, Australia, China, India and Brazil.

As a global leader in the production of medical cannabis, Aphria (TSX: APH) (OTCQB: APHQF) has a strong commitment to the production of high-quality, pure and safe cannabis. The company is leveraging a controlled growth system in which cannabis is cultivated only in the most natural conditions available in order to offer safe and consistent products. With different formulations in development, ranging from capsules to oral solutions and vaporizers, Aphria also provides a portal for both patients and health professionals to order their products. A team of experts is also available to answer any patient questions on issues relating to the use of cannabis in medical treatments. In June 2017, Aphria was granted a license by Health Canada to extend its cannabis production space by 57,000 square feet.

While its main focus is on regulating the nicotine levels in tobacco plants and producing very low nicotine tobacco as an aid to stop smoking, 22nd Century Group (NYSE: XXII), with its proprietary genetic engineering technology and expertise in plant breeding, is also an active player on the cannabinoid manufacturing market. Via wholly-owned subsidiary Botanical Genetics, LLC, the company has successfully created a type of industrial hemp that is completely THC-free. This is set to revolutionize the hemp industry by virtually guaranteeing a larger output, as, under current U.S. federal laws, any hemp plants with a THC concentration above 0.3 percent need to be destroyed. 22nd Century Group is also continuing research into the development of next-generation industrial hemp that will contain optimal levels of medically-relevant cannabinoids, as well as the creation of hemp varieties adapted to various climates around the world. The company has just ended its first industrial hemp field trials with the University of Virginia, a program that it plans to continue throughout 2018 with its zero-THC plants.

By using proprietary technology and systems, leading biotechnology companies in the field are not only spurring their own growth and development, but also spearheading a revolutionary approach to the production of pharmaceutical-grade cannabinoids and industrial hemp. These efforts will ultimately impact the entire industry and create growth opportunities for other cannabis companies, as well.

For more information on InMed Pharmaceuticals, please visit: InMed Pharmaceuticals, Inc. (CSE: IN) (OTCQB: IMLFF)
The QualityStocks Daily Newsletter http://Newsletter.QualityStocks.net

The QualityStocks Daily Blogs http://Blog.QualityStocks.net

Please read FULL Compensation Disclosures and other disclaimers at http://www.qualitystocks.net/disclaimer.php
QualityStocks
Site Admin
 
Posts: 1123
Joined: Mon May 21, 2007 7:58 pm
Location: Scottsdale, AZ

Re: InMed Pharmaceuticals, Inc. (IMLFF)

Postby QualityStocks » Thu Oct 26, 2017 5:27 pm

Innovative Biotechnology Companies are Transforming Cannabis-based Medical Products

NetworkNewsWire Editorial Coverage: Many biotech companies are taking advantage of widespread interest and acceptance of the potential for cannabis-based products to treat a range of medical disorders. These forward-thinking companies are developing proprietary systems and delivery methods to drive their research and development programs for a leading position in industry breakthroughs. Chief among them is InMed Pharmaceuticals, Inc. (CSE: IN) (OTCQB: IMLFF) (IMLFF Profile), which has made groundbreaking progress in the pre-clinical research and development of cannabinoids with its innovative proprietary biosynthesis process. One of the most established companies in this field, GW Pharmaceuticals plc (NASDAQ: GWPH), is a world leader in the development of orphan and non-orphan cannabinoid products to treat neurological conditions, while Zynerba Pharmaceuticals, Inc. (NASDAQ: ZYNE) is developing innovative cannabinoid therapeutics based on transdermal delivery mechanisms. While many biotechs rely on companies like Canopy Growth Corp. (OTC: TWMJF) (TSX: WEED) and Aurora Cannabis, Inc. (OTCQX: ACBFF) (TSX: ACB) as critical sources of the medical-grade cannabis needed to conduct their clinical research, InMed holds a unique position with its in-house capabilities.

Biotechs involved in the research, formulation, and testing of cannabis-based medical products from plant-based processes face the onerous regulatory processes imposed by the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA). The FDA’s scrutiny against such products stems from inconsistencies in active ingredient strength and quality, both of which may vary from one crop to the next. In addition, pesticides can be hard to remove, and crop fluctuations can affect yield. Producers are also often strained by the time, effort, and expense, not to mention chemical waste, required to manage high-yield cannabis crops.

Several biotechs have turned to chemical processes to produce synthetic cannabinoids which can deliver consistent outcomes every time, thereby overcoming some of these concerns and greatly increasing their prospects of gaining FDA approval. However, synthetic production can be expensive and can present potential safety issues. It is difficult to synthesize compounds that are identical to their natural counterparts, as the slightest structural variations can affect the quality and safety of the finished product.

A company that has developed a game-changing technology to bridge the best of both the natural and the synthetic manufacturing benefits is InMed Pharmaceuticals (CSE: IN) (OTCQB: IMLFF). Using an E. coli-based expression system, InMed has taken the lead by developing a biosynthesis process that uses cannabinoid DNA to create, in a controlled laboratory setting, compounds that are identical to those found in nature.

The company is the world’s first known company to utilize this biosynthesis manufacturing technique to create a biosynthetic cannabinoid for the treatment of glaucoma. Using this cannabinoid, InMed has formulated a hydrogel as a drug delivery mechanism for the eye condition. Normally, eyedrops are used to treat glaucoma through several applications a day. Conversely, the company’s medicated hydrogel forms a film over the eye and only needs to be applied once, at bedtime, to stay in place all night. InMed’s pharmaceutical-grade biosynthetic cannabinoids are identical to those found in nature and are more than 95% pure. They contain none of the mind-altering chemical in cannabis, tetrahydrocannabinol (THC), and are therefore free of any psychoactive properties.

Announcing a study co-sponsored by the University of British Columbia, InMed earlier this week achieved another industry first. The InMed-UBC study (http://nnw.fm/g3MWq) is the first ever to report hydrogel-mediated cannabinoid nanoparticle delivery to the eye resulting in enhanced drug uptake via the cornea and lens.

“Importantly, this study offers further validation of InMed’s capabilities in moving the science of cannabinoid pharmaceuticals forward,” InMed president and CEO Eric A. Adams stated in a press release. “Results like this, combined with our expanding patent portfolio and list of publications, on-going R&D, and renowned scientific team and collaborators demonstrates our depth of know-how and supports our trajectory to becoming an industry leader.”

The breakthrough that this achievement represents positions biosynthesis as the technology of the future for cannabinoid production across the board.

Companies, like InMed, that use biosynthesis for cannabinoid production can produce all of the active ingredients needed for their drugs in-house, eliminating the huge expenses of cannabis growing facilities and addressing other concerns. By eliminating the need for fertilizers and pesticides used in agriculture-based processing, biosynthesis is also a more eco-friendly and less harmful production methodology.

By leveraging its proprietary systems for bioinformatics and biosynthesis, InMed retains full control over its systems and processes, making it far easier to predict clinical outcomes. The company is scaling up its manufacturing process to complement its biosynthetic cannabinoid development program and to accommodate other biotech’s in their cannabinoid-based medical product developments. On September 12, 2017, InMed announced (http://nnw.fm/8hO3S) its filing of an application for a provisional patent covering its proprietary biosynthesis program, positioning the company for eventual protection of its technology in international jurisdictions.

With market capitalization of over $2.7 billion as of October 20, 2017, GW Pharmaceuticals (NASDAQ: GWPH) is a global leader in the development of plant-based cannabinoid therapeutics. Its primary focus to date has been on the development of cannabinoid products for the treatment of neurological conditions, including certain epilepsy syndromes. The company developed the world’s first cannabis-based prescription drug for the treatment of spasticity as a result of multiple sclerosis. GW has other product candidates in its development pipeline, including formulations for the treatment of glioma and schizophrenia.

Zynerba Pharmaceuticals (NASDAQ: ZYNE) focuses on the development of transdermal delivery methods for synthetic cannabinoid therapeutics. The company’s pipeline includes ZYN002, a patented gel containing synthetic cannabidiol (CBD), a non-psychoactive cannabinoid, for transdermal delivery to patients with osteoarthritis and Fragile X syndrome. It is also targeted for adults with focal seizures. On September 28, 2017, company shares rocketed by 54% in afternoon trading following the announcement of positive results from mid-stage testing of ZYN002. Zynerba’s other product in development, ZYN001, is a THC-based drug for the relief of pain associated with fibromyalgia and peripheral neuropathic indications.

Canopy Growth (OTC: TWMJF) (TSX: WEED) operates the largest cannabis growing greenhouses in the world, covering over 350,000 square feet. With a market cap of almost $2.2 billion as of October 20, 2017, the company supplies medical grade cannabis via one of its core brands, Bedrocan Canada, a branch of Netherlands-based Bedrocan International. Canopy places a high priority on producing consistent quality and providing a critical service to biotechs. The company’s high-quality medical grade cannabis is used for clinical research in several countries in Europe. Via Bedrocan, Canopy Growth recently launched the EQUAL Study, one of the largest clinical studies of its kind, to assess the effects of medical cannabis use on quality of life.

Aurora Cannabis (OTCQX: ACBFF) (TSX: ACB), based in Canada, is another grower of medical grade cannabis with a smaller market cap of $814 million as of October 20, 2017. The company supplies both dried cannabis and high-margin cannabis oils. Registered physicians and patients are offered a portal by the company for the servicing prescriptions of their products. Growth in its customer base and the average price per gram of product sold were noted by Aurora as the reason for its fourth-quarter revenues of $5.9 million in 2017.

All of these companies show a commitment to developing innovative technologies and proprietary systems to drive their businesses. The success and growth of these enterprises indicate that the emerging cannabinoid-related medical product sector has a bright future.

For more information on InMed Pharmaceuticals, please visit: InMed Pharmaceuticals, Inc. (CSE: IN) (OTCQB: IMLFF)
The QualityStocks Daily Newsletter http://Newsletter.QualityStocks.net

The QualityStocks Daily Blogs http://Blog.QualityStocks.net

Please read FULL Compensation Disclosures and other disclaimers at http://www.qualitystocks.net/disclaimer.php
QualityStocks
Site Admin
 
Posts: 1123
Joined: Mon May 21, 2007 7:58 pm
Location: Scottsdale, AZ

Re: InMed Pharmaceuticals, Inc. (IMLFF)

Postby QualityStocks » Tue Oct 31, 2017 4:18 pm

Economic Impact of Biosynthesis on the Cannabis Industry

NetworkNewsWire Editorial Coverage: According to a recent Haywood Securities research report, the value of the cannabidiol (CBD) market is expected to hit $2.1 billion by 2020. CBD is just one compound out of more than 90 found within the cannabis plant, though. While many companies with an interest in medicinal marijuana pursue various avenues to extract cannabinoids, InMed Pharmaceuticals, Inc. (CSE: IN) (OTCQB: IMLFF) (IMLFF Profile) has developed a proprietary process capable of extracting all 90+ cannabinoids in a laboratory setting, eliminating most of the costly requirements that typically come with cannabinoid extraction. To understand the value of this process, it helps to take a look at the methods utilized by other industry players such as GW Pharmaceuticals (NASDAQ: GWPH) and Zynerba Pharmaceuticals, Inc. (NASDAQ: ZYNE), as well as the challenges of high-volume cannabis cultivators like Aurora Cannabis, Inc. (TSX: ACB) (OTCQX: ACBFF) and Canopy Growth Corp. (TSX: WEED) (OTC: TWMJF).

Fueled by mounting increases in consumer demand and expanding legalization, the race is on to find a cost effective method of extracting medicinal-grade cannabinoids. To glean pharmaceutically-viable cannabinoid compounds, cannabis must first be physically grown in quantity. Then, the cannabinoids are extracted and processed in an attempt to meet the exacting purity levels required by regulatory standards. Sourcing cannabinoids naturally requires planting, growing, harvesting, extracting and purifying huge quantities of plants. Breath of Life Pharma, recently featured in a Rolling Stone article, had to dedicate one million square feet of cannabis cultivation space in order to produce enough raw flower for its extraction business. Producing compounds from plant extracts is time consuming and expensive, and, despite cultivating thousands of tons of cannabis, most companies in this arena can only produce a couple of the 90+ cannabinoids present in the plant. Many cannabinoids are found only in trace amounts and will never be accessible or economically feasible with current extraction methods.

Dedicated real-estate, facility maintenance and operating costs are all requisite for cultivation, making cannabinoid production a cumbersome and costly business. There are also ongoing concerns with growers resorting to the use of fertilizers, pesticides and herbicides to produce healthier crops and improve yields. Such actions can introduce toxic substances into edible and pharmaceutical-grade cannabinoid extracts.

With capital intensive infrastructure investment, weather and facility risks, on-going operating costs and contamination possibilities, cannabis companies may soon rely on natural and chemical synthesis processes to extract valuable cannabinoid compounds for use in medicinals and potential new pharmaceutical drug development.

Meaningful economic impact on profits should easily accrue to cannabis companies capable of shedding all the costs and challenges associated with current cultivation to extraction methods. InMed Pharmaceuticals (CSE: IN) (OTCQB: IMLFF) is scientifically bypassing the horticultural approach to cannabinoid production by developing a robust, high-yield biosynthesis process. The company’s proprietary cannabinoid manufacturing process combines the inherent safety and known efficacy of natural drug structures with the convenience, control and quality of a laboratory-based manufacturing process. InMed’s innovative process targets significant cost savings as well as enhanced production, purification and quality control compared to existing grow-harvest-extract-purify methods employed by other companies. With similar scientific approaches used in multiple pharmaceutical applications, InMed’s biosynthesis system will allow the extraction of all of the 90+ naturally occurring cannabinoids. InMed’s proprietary biopharmaceutical approach to the production of pharmaceutical grade, bio-identical cannabinoids is a transformative technology in the rapidly emerging cannabinoid pharmaceutical, nutraceutical and medicinal sectors.

Using its exclusive process in a controlled laboratory setting, InMed’s scientists can create cannabinoid compounds that are identical to those found in nature without the difficult, expensive and time-consuming challenges of planting, growing and harvesting cannabis then laboriously extracting the individual cannabinoids for medical use. It also completely eliminates any need for fertilizers or pesticides. To protect this valuable asset, InMed recently filed a provisional patent for biosynthesis of cannabinoids. Once converted into an International Patent Cooperation Treaty (PCT) application, InMed will aggressively pursue key international jurisdictions.

“This novel approach to the biosynthesis of cannabinoids is a game-changer for drug development. The importance of producing cannabinoids that are identical to the naturally occurring compounds cannot be overstated. Many drug development efforts with synthetic derivatives have failed,” Dr. Vikramaditya Yadav, assistant professor of Chemical and Biological Engineering at the University of British Columbia, a co-inventor of the biosynthesis technology, stated in a news release announcing the filing (http://nnw.fm/WJ8zY).

On the cusp of revolutionizing cannabinoid extraction, InMed is assembling the world’s leading experts to assist with advancing its biosynthesis technology toward commercialization. In September, InMed retained Ben Paterson, P.E. as a consultant to help define the pathway for the scale-up, purification, and manufacturing strategies for InMed’s cannabinoid biosynthesis program (http://nnw.fm/pY34f). Paterson has nearly 40 years’ experience developing pharmaceutical manufacturing and purification processes. He devoted 24 of his 37 years as a senior engineering advisor at Eli Lilly in the company’s biosynthesis division. His expertise in this arena includes the design, construction, operation, optimization, and troubleshooting of both large and small molecule drug facilities, including the E. coli biosynthesis of numerous products.

No other extraction method reduces the cost or time required to create pharmaceutically-viable cannabinoid compounds like InMed’s. Other companies depend on the expertise of outside cultivators.

GW Pharmaceuticals’ (NASDAQ: GWPH) strategy is to engage a UK-based greenhouse grower to cultivate cannabis for its Epidiolex treatment. In 2016, GW Pharmaceuticals entered into a partnership with British Sugar that saw the cultivator switch from growing tomato plants to cannabis. The long-term contract involves growing marijuana plants in an 18-hectare greenhouse complex in Wissington, Norfolk, UK, to support GW’s development of a childhood epilepsy drug. It is expected that the crop will yield enough cannabis to treat 40,000 children per year globally. However, the production process still requires a great deal of expense, including electricity, lighting, heating, real estate costs and other resources that could potentially cost tens of millions of dollars, or more – racking up considerable costs compared to InMed’s ability to extract cannabinoids in a laboratory setting.

Zynerba Pharmaceuticals (NASDAQ: ZYNE) is crafting synthetic cannabinoid development techniques. Unlike InMed’s platform, these will not mimic naturally occurring cannabinoids, but will be derived from chemicals. Zynerba has been working on cannabinoid-based treatments for several major health conditions. In addition to epilepsy, fibromyalgia and Fragile X syndrome, the company has developed a synthetic transdermal cannabinoid product in the form of a gel that enables compounds to pass through the skin and into the blood stream. A skin patch is also available. Zynerba claims that its product candidates are produced in accordance with regulatory requirements, are consistent in potency and have no impurities. However, the company recently reported disappointing top-line results from its phase II study of ZYN002, a synthetic CBD-formulated permeation-enhanced gel for transdermal delivery.

For nearly 17 years, traditional cannabis producers in Canada have struggled with capital infrastructure investment, environmental risks and the open-ended costs of production, believing that somehow they’ll become more profitable by reaching economies of scale. Overseen by government-mandated quality controls, it’s a capital intensive business no matter the size of production.

With the incumbent operating costs of an 800,000 square foot building, Aurora Cannabis (TSX: ACB) (OTCQX: ACBFF) is one of the largest producers of medical cannabis in Canada. However, even large licensed producers are susceptible to the vagaries of marijuana cultivation and cannabinoid extraction. In January, the company announced a government-initiated Type II voluntary recall of its products, with some of its marketed offerings containing “residual levels of myclobutanil and/or bifenazate that exceed any of the levels permitted in food production for these two pesticides.” Unfortunately for Aurora and all other producers, any trace of pesticides is compounded during cannabinoid extraction. The long-term ramifications of the recall are difficult to ascertain but certainly carry a financial and reputational impact. The company’s cannabis oil extracts represent about 26 percent of gross revenues. Biosynthesis produces 99%+ pure cannabinoids with no possibility of contamination, since no plant material, fertilizers or pesticides are ever used.

Canopy Growth Corp. (TSX: WEED) (OTC: TWMJF) has publicized its automated, data-driven processes, lean operation and climate control systems, but it is still dependent on large parcels of land and significant capital. Canopy is the parent company of licensed cannabis producers Tweed Inc., Tweed Farms Inc., Bedrocan Canada Inc. and newly-acquired Mettrum Health Corp, giving Canopy a combined growing platform featuring over 665,000 sq. ft. of production space. The company has also acquired part or full ownership of other cannabis producers and distributors. Although it may be a “data-driven” mega producer, Canopy is still subject to capital outlays, significant operating costs and continuous quality control concerns.

The cost of cannabis production for extracts is fast becoming a leading concern of cannabis growers and producers, especially those looking to establish a reputation for quality and consistency in addition to locking in long-term profitability in the burgeoning marijuana market. The enormous profit potential of cannabis production is offset by the vagaries of production and labor costs, varying quantity yields, environmental risk, impurities and limited cannabinoid compound extraction. InMed is at the vanguard of cannabinoid production with its ability to biosynthesize any cannabinoid in the laboratory. InMed’s proprietary cannabinoid manufacturing system provides a scientific method to cost-effectively produce larger volumes of guaranteed high-quality compounds. This unique ability places InMed in an enviable position as both the medicinal and recreational marijuana markets continue to surge.

For more information on InMed Pharmaceuticals, please visit: InMed Pharmaceuticals, Inc. (CSE: IN) (OTCQB: IMLFF)
The QualityStocks Daily Newsletter http://Newsletter.QualityStocks.net

The QualityStocks Daily Blogs http://Blog.QualityStocks.net

Please read FULL Compensation Disclosures and other disclaimers at http://www.qualitystocks.net/disclaimer.php
QualityStocks
Site Admin
 
Posts: 1123
Joined: Mon May 21, 2007 7:58 pm
Location: Scottsdale, AZ

Re: InMed Pharmaceuticals, Inc. (IMLFF)

Postby QualityStocks » Fri Nov 03, 2017 4:18 pm

NetworkNewsBreaks – InMed Pharmaceuticals, Inc. (CSE: IN) (OTCQB: IMLFF) Unlocks Ability to Produce 90+ Cannabinoids through Biosynthesis

Preclinical stage biopharmaceutical company InMed Pharmaceuticals, Inc. (CSE: IN) (OTCQB: IMLFF) continues to advance its drug development programs through the use of its proprietary bioinformatics database assessment tool. An article discussing this reads: “InMed Pharmaceuticals, Inc. (CSE: IN) (OTCQB: IMLFF) continues down the fast track with its proprietary technology for the microbial biosynthesis of cannabinoids (http://nnw.fm/tP4jS). The company recently announced it has enabled the production of all four “gateway” cannabinoids using genetically engineered microorganisms. From these gateway substrates, production of all 90+ cannabinoids is possible via biosynthesis. InMed’s breakthrough stands to make the production of cannabis derivatives, including THC, CBD and trace cannabinoids, a much more commercially feasible proposition. The Company currently has two lead drug candidates that employ combinations of cannabinoids as the active ingredients. Moreover, as if to put a seal on its step forward, InMed is now included in the CSE25 Index, since it is now one of the 25-largest companies in the CSE Composite Index.”
The QualityStocks Daily Newsletter http://Newsletter.QualityStocks.net

The QualityStocks Daily Blogs http://Blog.QualityStocks.net

Please read FULL Compensation Disclosures and other disclaimers at http://www.qualitystocks.net/disclaimer.php
QualityStocks
Site Admin
 
Posts: 1123
Joined: Mon May 21, 2007 7:58 pm
Location: Scottsdale, AZ

Re: InMed Pharmaceuticals, Inc. (IMLFF)

Postby QualityStocks » Tue Nov 07, 2017 6:07 pm

Biotech M&A Momentum Attractive for Cannabinoid R&D Space

NetworkNewsWire Editorial Coverage: Morgan Stanley’s research team in January 2017 forecast that biotech-pharmaceutical companies – with a combined $75 billion in cash on hand – would strategize to boost revenue growth through mergers and acquisitions of smaller companies with high-potential product pipelines (http://nnw.fm/mN24x). Growth via strategic acquisition makes more sense to cost-conscious Big Pharma than does shelling out $2.55 billion (http://nnw.fm/3Qr3S) to develop a new drug in-house. With growing interest in the convergence of cannabis and medicine, companies like InMed Pharmaceuticals, Inc. (CSE: IN) (OTCQB: IMLFF) (IMLFF Profile), which has an innovative biosynthesis technology that addresses the regulatory concerns associated with consistent pharmaceutical-grade cannabinoids and logistical constraints on development, may find themselves on the radar of Big Pharma. Mid-tier cannabinoid developers such as Zynerba Pharmaceuticals, Inc. (NASDAQ: ZYNE) and Axim Biotechnologies, Inc. (OTCQB: AXIM) are also developing cannabinoid-based therapies, possibly on track for the same opportunity seen in the $847 million acquisition of Scioderm by Amicus Therapeutics, Inc. (NASDAQ: FOLD). According to Thompson Reuters, pharma deals in 2015 increased 94 percent to $59.3 billion over the prior year, which adds weight to Morgan Stanley’s projections, and GW Pharmaceuticals’ (NASDAQ: GWPH) position as the leader of the Marijuana Index biotech sector demonstrates how biotechs continue to drive value in the broader, acquisition-hungry pharmaceutical sector.

Global pharma and life sciences M&A values slumped over 60 percent in Q3 of this year, as compared to Q2, in all subsectors except biotech, according to Pricewaterhouse Coopers. Large companies losing revenue amid expiring patents and facing costly R&D is a pattern baked into the biotech market. As such, the acquisition of revenue-producing biotechs as a solution is a trend that will most likely hold fast in upcoming years. Such a robust, underlying market environment is great news for cannabinoid biosynthesis pioneer InMed Pharmaceuticals, Inc. (CSE: IN) (OTCQB: IMLFF), the developer of a proprietary, scalable biosynthesis process capable of manufacturing all of the more than 90 naturally-occurring cannabinoids at pharmaceutical grades in-house – a rare and possibly unattained ability for everyone else in the industry. What this means is that InMed provides a solution to a main hindrance of U.S. FDA approval of cannabinoid-based therapies: producing consistent, pharmaceutical-grade cannabinoids that are identical to those found in nature.

This capability also enables InMed to cost-effectively produce its own high-yield cannabinoids for its product pipeline, rather than outsourcing cultivation as does industry giant GW Pharmaceuticals and other cannabis-focused biotechs. InMed’s lead product, INM-750 (http://nnw.fm/0Q5ia), is a topical product designed to treat epidermolysis bullosa (EB), a rare disease of the skin’s connective tissues, for which there is a significant unmet medical need and no currently approved treatments. INM-750 contains a combination of biosynthetically-produced cannabinoids carefully selected to modulate levels of the key keratins (proteins) that are absent in EB patients and, thereby, it is hoped, modulate the disease itself. INM-750 is also designed to address the numerous symptoms of EB such as inflammation, wound healing, skin regeneration, itching, and pain.

Because INM-750 will be the first therapy of its kind, InMed filed an international Patent Cooperation Treaty (PCT) application to commercially protect this valuable IP across the participating 151 PCT member countries. Given the well-documented multi-mechanism anti-inflammatory, analgesic and wound healing properties of various cannabinoid compounds, as well as InMed’s emerging pre-clinical data on the use of cannabinoids for the treatment of EB, the company is taking all the necessary steps to lock in access to what it sees as a potential $1 billion global market. InMed has even tapped advanced human tissue-engineering company ATERA SAS of France to develop 3D human skin models engineered from cells of EB patient biopsies in an effort to aid in the investigation of INM-750’s impact at ultra-structural cellular and molecular levels via in vitro models using both normal skin cells and EB-derived skin cells.

With a market cap of just over US$45 million, InMed boasts a rare position as the owner of proprietary biosynthesis and bioinformatics technologies (http://nnw.fm/e069N) and is developing the technology to produce commercial quantities of cannabinoids without the production and maintenance costs and pitfalls associated with chemically-derived cannabinoid synthetics. InMed’s approach to developing biosynthetic cannabinoids combines the inherent safety and established efficacy of natural drug structures with the kind of quality-controlled pharmaceutical manufacturing required by the FDA. This process also grants the company direct access to overlooked minor cannabinoids that are currently economically unfeasible to extract from the plant. Combining these advantages with the company’s ability to rapidly identify and develop additional indications such as the company’s INM-085 for the >$5 billion glaucoma market, or INM-405 for pain, results in all the right ingredients to potentially make InMed one of the sector’s next big stars or M&A targets.

As noted earlier, the Scioderm acquisition is a hallmark demonstration of the potential for companies with clinical success, as at one point it was in a similar position before being acquired by Amicus Therapeutics (NASDAQ: FOLD) for nearly $850 million. Scioderm’s development of Zorblisa™, its only asset that was a promising topical wound-healing agent for EB patients, made a natural and accretive opportunity for Amicus’ IP portfolio. Notably, Scioderm’s acquisition in 2015 by Amicus followed phase 2b study results from 42 patients. JP Morgan and Cowen estimate peak sales for a product in EB to treat only the symptoms will be USD$900 million-$1.2 billion (http://nnw.fm/fL6VH).

This acquisition story not only emphasizes the value of biotech to the pharmaceutical industry, but also demonstrates the potential for cannabinoid-based candidates from companies like InMed and Zynerba Pharmaceuticals (NASDAQ: ZYNE), which is focused on transdermal synthetic cannabinoids such as ZYN002, a first-of-its kind synthetic cannabidiol formulated as a patent-protected and permeation-enhanced gel. ZYN002 has been granted Orphan Drug Designation in a genetic developmental and cognitive syndrome known as Fragile X and is also being developed as a treatment for refractory epilepsy and osteoarthritis of the knee. ZYN002 recently met its primary endpoint in an open label exploratory phase 2 clinical trial, with a 46 percent improvement in patients’ total ADAMS score (Anxiety, Depression, and Mood Scale). This clinical-stage cannabinoid developer was recently added to the Russell 3000® Index. Zynerba is currently valued at $130+ million.

Axim Biotechnologies (OTCQB: AXIM) announced in an October release news of the USPTO’s allowance of the company’s December 2015 patent filing for an “ophthalmic solution comprising cannabinoids for the treatment of glaucoma and symptomatic relief of conjunctival inflammation.” This notice of allowance extends the company’s already firm footing in cannabis-based pharmaceutical, nutraceutical and cosmetic products. Its position has been established by such products as the company’s CBD-based, controlled release chewing gum CanChew+®, as well as the combination CBD/THC gum MedChew Rx®. Axim has a market cap of $350 million.

GW Pharmaceuticals (NASDAQ: GWPH) is a great example of the kind of success possible in in today’s biotech space. GW Pharmaceuticals’ share price has increased over 1,000 percent from humble beginnings in 2013 when the company closed its IPO at $8.90 per share. Since then, it has transformed into a sector powerhouse with a market valuation of more than $2.8 billion, trading in a 52-week range of $92.65-$136.95. This share-price performance precedes the anticipated receptivity by both the health care market and the FDA to indications such as the company’s Epidiolex® (plant-derived cannabidiol) for severe, orphan, early-onset, treatment-resistant epilepsy syndromes, including Dravet syndrome and Lennox-Gastaut syndrome (LGS). The company has received Rare Pediatric Disease and Orphan Drug Designations for Epidiolex in both syndromes, as well as Fast Track Designation in Dravet syndrome, and it recently completed the rolling submission of a New Drug Application for Epidiolex as an adjunctive treatment of the seizures associated with both (http://nnw.fm/C2ybx). With three phase 3 Epidiolex safety and efficacy studies under its belt, each of which met primary endpoints with good tolerability, GW Pharmaceuticals continues to establish itself as a vanguard for cannabinoid therapeutics.

Whether it is commercial success with a novel drug to satisfy an unmet medical need or a buyout by a major player in the sector that wants to forego the risk and cost of developing a new drug in-house, the future looks bright for successful cannabinoid therapy innovators amid robust and ongoing biotech M&A activity. The cannabinoid medicines game is just getting started, and there are already projections for the global medical marijuana market alone to reach some $55.8 billion by 2025, growth which is said to be due, in large part, to the mounting number of therapeutic applications of the drug.

For more information on InMed Pharmaceuticals, visit: InMed Pharmaceuticals, Inc. (CSE: IN) (OTCQB:
The QualityStocks Daily Newsletter http://Newsletter.QualityStocks.net

The QualityStocks Daily Blogs http://Blog.QualityStocks.net

Please read FULL Compensation Disclosures and other disclaimers at http://www.qualitystocks.net/disclaimer.php
QualityStocks
Site Admin
 
Posts: 1123
Joined: Mon May 21, 2007 7:58 pm
Location: Scottsdale, AZ

Re: InMed Pharmaceuticals, Inc. (IMLFF)

Postby QualityStocks » Wed Nov 08, 2017 5:50 pm

Cannabis Biotechs Could be Big Pharma’s Latest M&A Focus

NetworkNewsWire Editorial Coverage: In late October, President Donald Trump called the ongoing opioid epidemic the “worst drug crisis in American history” before declaring it a public health emergency and pledging the nation’s full resolve in overcoming it. These efforts could mark a changing of the tides as they relate to opioid painkillers, and Big Pharma is already eyeing its next moves. As reported by Reuters in June of this year, a handful of major drug makers are exploring M&A opportunities within the cannabis-based pain reliever market in hopes of cashing in on rising demand for opioid substitutes and a variety of other indications for which cannabis-based therapies show considerable market potential. InMed Pharmaceuticals, Inc. (CSE: IN) (OTCQB: IMLFF) (IMLFF Profile), with its promising drug development indications and noteworthy IP assets, is one biotech that could be well-positioned to benefit from Big Pharma’s shifting focus toward the cannabis market. As demonstrated by the holdings and acquisition activities of CannaRoyalty Corp. (OTCQX: CNNRF), Aphria, Inc. (OTCQB: APHQF), Maricann Group, Inc. (CSE: MARI) and Aurora Cannabis, Inc. (OTCQX: ACBFF), InMed’s promising biosynthesis platform could put it on the radar of some major names seeking entry into one the pharmaceutical industry’s fastest-growing sectors.

Big Pharma’s mass entry into the cannabis space may well be on the horizon, but most industry analysts agree that M&A activity targeting existing cannabis biotechs, not internal research and development efforts, will provide the primary entry pathway. This reliance on M&A deals instead of R&D dollars has become a driving trend in the pharmaceutical industry in recent years, with the value of such transactions hitting $59.3 billion in 2015. The cannabis industry, in particular, features a host of inherent costs, including: dedicated real estate, facility maintenance, and operating expenses, which are requisite for cultivation and subsequent testing. When paired with risks of crop recalls and ongoing concerns related to the use of fertilizers, pesticides and herbicides to improve yields, these factors serve as sizable barriers to entry for relatively inexperienced pharmaceutical firms looking to cash in on the cannabis boom. Additionally, many of these firms with strategic plans for overseas expansion will face an increased level of regulatory burden on plant based products.

These barriers to entry make InMed Pharmaceuticals, Inc. (IMLFF Profile), with its proprietary in-house cannabinoid biosynthesis platform, an interesting player in the cannabis biotech market. Biosynthesis mimics the cannabinoid-creation process utilized by plants to create pure, individual cannabinoids that are devoid of the by-products and impurities found with extraction. InMed’s method introduces the DNA of individual cannabinoids into E. coli bacteria and leverages an advanced biofermentation process that is both laboratory-based and tightly controllable. This process virtually eliminates the quality and consistency concerns that plague more traditional and antiquated extraction techniques. Using this platform, InMed is capable of producing any of the 90+ “downstream” cannabinoids that occur naturally in the cannabis plant. With the value of the cannabidiol (CBD) market alone in the U.S expected to hit $2.1 billion by 2020, the market potential of InMed’s biosynthesis IP is substantial, and its development pipeline provides a taste of the impact that this technology could have moving forward.

“This novel approach to the biosynthesis of cannabinoids is a game-changer for drug development,” Dr. Vikramaditya Yadav, Assistant Professor of Chemical and Biological Engineering at the University of British Columbia and co-inventor of InMed’s biosynthesis technology, stated in a recent news release. “The importance of producing cannabinoids that are identical to the naturally occurring compounds cannot be overstated. Many drug development efforts with synthetic derivatives have failed.”

InMed’s lead product candidate is INM-750, a cannabinoid-based topical therapy being developed as a treatment for epidermolysis bullosa (EB). An orphan disease with no known treatment and significant unmet medical need, EB consists of a group of inherited connective tissue disorders sharing a common manifestation of extremely fragile skin that blisters or tears from friction or slight trauma. With INM-750, InMed is attempting to harness the well-documented anti-inflammatory, analgesic and would healing properties of cannabinoid compounds to address these key disease hallmarks. In early March, InMed announced its filing of an international Patent Cooperation Treaty (PCT) application covering INM-750, marking an important step toward providing intellectual and commercial protection of the product as a topical therapy for EB.

Joining INM-750 in InMed’s development portfolio are INM-085, for the treatment of glaucoma, and INM-405, which focuses on the pain-relieving benefits of CBD. As noted on the company’s website, INM-085 under development for the treatment of glaucoma, is a multi-target, dual-mechanism of action therapy, utilizing multiple cannabinoids for optimal efficacy. Implementing a proprietary polymer-based formulation designed to enable simple, once-a-day application, InMed’s INM-085 formulation could prove to be a game-changer in the glaucoma treatment market, which is expected to exceed $3 billion by 2023, according to research and consulting firm GlobalData. As announced late last month, InMed, in partnership with the University of British Columbia, recently completed a study that was the first to report hydrogel-mediated cannabinoid nanoparticle delivery to the eye, with endpoints demonstrating enhanced drug uptake via the cornea and lens.

INM-405, though earlier in development than InMed’s leading product candidates, has also shown promising proof-of-concept data. Just last month, the company announced results from pre-clinical testing suggesting that “peripheral application of certain cannabinoid compounds, alone or in combination, is effective in the treatment of craniofacial muscle pain disorders, without any observed CNS side effects, and may be a more desirable strategy than systemic pain-relief administration.” As noted in a recent news release, InMed has already filed a provisional patent application in the United States protecting INM-405, as well as other unique compositions as cannabinoid-based topical therapies for the treatment of pain. This program and its related IP, when combined with InMed’s proven biosynthesis platform, could place it firmly on the radar of Big Pharma players and other holding firms interested in staking a claim in what could be the next big thing in pain relief, particularly as the opioid crisis continues to grab headlines.

When considering M&A activity within the cannabis industry, the portfolio of specialized holding company CannaRoyalty Corp. (OTCQX: CNNRF) is a good place to start. Describing itself as “an integrated platform designed for commercialization in three high-value segments of the global cannabis market,” CannaRoyalty’s brands are divided into three unique categories – research/IP, retail and industry infrastructure. Alongside North American research groups BAS Research and Bodhi R&D Inc., Anandia Labs, in which the company acquired a 20 percent equity stake earlier this year, anchors CannaRoyalty’s research/IP arm with its focus on cannabis testing, extraction and genetics.

Similar limitations impact the likes of Aphria, Inc. (OTCQB: APHQF), Maricann Group, Inc. (CSE: MARI) and Aurora Cannabis, Inc. (OTCQX: ACBFF). All licensed producers and distributors of medical marijuana, each of these companies has demonstrated interest in expanding its position in the cannabis market through investment or acquisition in recent months. In mid-August, Aphria announced an $11.5 million investment in Scientus Pharma, a vertically-integrated biopharmaceutical firm conducting research on cannabinoids with a special focus on commercializing pharmaceutical-grade cannabinoid derivative products. Scientus utilizes a patent-pending commercial scale microwave extraction platform to formulate these products, meaning that traditional cultivation operations, along with inherit concerns regarding the potential use of fertilizers, pesticides and herbicides, still impact development efforts.

In August, Maricann Group expanded its foothold in the cannabis industry through its purchase of NanoLeaf Technologies Inc. NanoLeaf is perhaps best known for its development, in partnership with Vesifact, of a standardized dose soft gel capsule for cannabinoid-based pharmaceutical Vesisob. Because cannabinoids are fat-soluble compounds, they have characteristically low dissolution rates and unpredictable oral availability. The presence of this bio-delivery technology within NanoLeaf’s IP portfolio was noted, in the announcing news release, as a key driver for Maricann’s decision to purchase the company. This is a promising factor for other industry upstarts with innovative bio-delivery IP targeting the cannabinoid space, such as the proprietary hydro-gel delivery mechanism employed by InMed’s INM-085 product candidate.

Through its investment in Hempco in September, licensed medical cannabis producer Aurora Cannabis once again highlighted the active M&A scene in the cannabis industry. In a news release announcing the investment, Aurora CEO Terry Booth noted that the transaction served as a way of “securing a potentially material source of raw CBD material for [Aurora’s] medical concentrates business.” Per its investor presentation, Hempco primarily sources farmed hemp seeds from local Canadian farmers and processes them as a source of oils and protein powders. While utilizing this infrastructure to extract CBD for product development isn’t yet an option, Charles Holmes, CEO of Hempco, highlighted it as a potential benefit moving forward, stating “[I]f the current regulations prohibiting the extraction of cannabidiol (CBD) from hemp products were to change, which we anticipate will happen in the near to mid-term future, Hempco will be very well positioned to capitalize on this opportunity through its relationship with Aurora.”

The promise of cannabinoids as pharmaceutical products targeting a wide range of currently-underserved indications has led to significant M&A activity throughout the cannabis industry. While the majority of market players have been forced to rely on traditional cultivation operations to source the cannabinoids needed to develop these products, forecast supply shortages loom large, particularly in Canada. By dodging this supply dearth and effectively eliminating quality concerns that can plague cannabis cultivation operations, InMed Pharmaceuticals, with its biosynthesis technology and promising development pipeline, has established itself as a company to watch as Big Pharma begins to set its sights on the future of pain relief and the increasing value of biotechs to the cannabis industry.

For more information on InMed Pharmaceuticals please visit: InMed Pharmaceuticals, Inc. (CSE: IN) (OTCQB: IMLFF)
The QualityStocks Daily Newsletter http://Newsletter.QualityStocks.net

The QualityStocks Daily Blogs http://Blog.QualityStocks.net

Please read FULL Compensation Disclosures and other disclaimers at http://www.qualitystocks.net/disclaimer.php
QualityStocks
Site Admin
 
Posts: 1123
Joined: Mon May 21, 2007 7:58 pm
Location: Scottsdale, AZ

Re: InMed Pharmaceuticals, Inc. (IMLFF)

Postby QualityStocks » Tue Nov 14, 2017 5:55 pm

Biosynthesis: Making the Impossible Possible in Medicinal Cannabis

NetworkNewsWire Editorial Coverage: The U.S. pharmaceutical industry is pocked with pitfalls that make it difficult for the development of cannabis-based drugs. To receive FDA approval, drug manufacturers must produce a consistent, pharmaceutical-grade product. Drug researchers with cannabis-based candidates are largely dependent on cannabis producers to access their drug raw materials. And therein lies the issue. The cannabis production sector has had its share of product recalls, and is saddled with pricey cost of commercial cultivation. The roadblocks are considerable – from legal and execution standpoints – making these efforts not quite impossible but certainly, currently, difficult. Canada-based biopharmaceutical company InMed Pharmaceuticals, Inc. (CSE: IN) (OTCQB: IMLFF) (IMLFF Profile) is taking these challenges head-on, and has broken new ground with an innovative, proprietary biosynthesis process that reliably creates pure cannabinoids. This process is capable of making any of the 90+ individual cannabinoids, under strict quality control resulting in >95% purity with no pesticides, and in a consistent fashion – factors that current plant growing methods of production cannot accomplish. Biosynthesized product with consistently high purity and quality poses a considerable advantage over the medical marijuana used by companies like CanniMed Therapeutics, Inc. (TSX: CMED) (OTC: CMMDF) (FRA: 0GB), which cultivates its own cannabis for its product pipeline. Any biotech company seeking to develop cannabinoid-based drugs could benefit from InMed’s unique approach. Currently, these biotech companies are dependent on growers like Aurora Cannabis, Inc. (TSX: ACB) (OTCQX: ACBFF), Canopy Growth Corp. (TSX: WEED) (OTC: TWMJF) and Aphria, Inc. (TSX: APH) (OTC: APHQF) to supply the raw flower or specific cannabinoid extracts needed, albeit only a few cannabinoids can be economically extracted from the plant. Such extracted product may not have the purity or consistency required to qualify as an FDA-approved pharmaceutical ingredient.

The extraction techniques from plant-growing operations are subject to high fluctuation in drug concentration, as flowers from the same marijuana plant display high fluctuations in drug composition. A key factor in receiving formal drug approval from regulatory authorities includes product consistency, which may be one reason the FDA, to date, has never approved a botanically-derived marijuana drug. A few synthetic cannabinoid-based drugs have, however, been approved by the FDA (http://nnw.fm/dyD4o), and experts believe marijuana’s only future as a medicine in the U.S. is through its isolated, pure cannabinoid components and their synthetic counterparts.

While manufacturing synthetic cannabinoids is a potential means of sidestepping the various prohibitive aspects of agricultural cannabis production, many development efforts in this area have failed. Various companies have attempted to chemically synthesize cannabinoid compounds for pharmaceutical application, but the primary restrictive factor is the difficulty of duplicating these compounds in a way that makes them identical to the naturally-occurring ones. Even a slight variation in structure can mar the efficacy and safety of synthetic cannabinoid compounds, and, as with natural sourcing, the time drain, expense and tedium of the synthetic manufacturing process (along with the large quantities of chemical waste it creates) make it a problematic enterprise.

InMed Pharmaceuticals, Inc. (CSE: IN) (OTCQB: IMLFF) breakthrough biosynthesis process allows it to control the entire drug development process, in house – and without the inherent challenges of traditional agricultural cultivation methods.

Biosynthesis, or the process of producing complex molecules within living organisms or cells, is currently employed in various industrial applications, including using bacteria or yeast-based systems to produce pharmaceuticals. InMed’s proprietary, pioneering approach to cannabinoid biosynthesis is truly a drug development game changer that has the potential to overcome FDA regulatory hurdles and bypass the other shortcomings associated with botanical cannabis cultivation. This process could open up several possibilities in terms of improving consistency and enabling biotechs to harness the potential of all cannabinoids.

InMed employs an E. coli-based expression system for manufacturing cannabinoids that has proven internally to be much more efficient and robust than other microbial platforms, and this system enables the high-yield manufacturing of all 90+ naturally occurring cannabinoids, combining the intrinsic safety and known effectiveness of natural drug structures with the control, quality and convenience of lab-based manufacturing.

Employing this exclusive process in a controlled lab setting, scientists at InMed are able to create cannabinoid compounds that are identical to those that occur naturally while eliminating problems associated with inconsistency and contamination from pesticides.

Aside from inconsistency issues, another stumbling block on the botanical marijuana side is the difficulty of extracting compounds from the cannabis plant in adequate amounts and purities to pharmaceutically test them. Natural sourcing of most cannabinoid compounds is very time-consuming, difficult, expensive, inconsistent (as previously mentioned) and low-yielding. The natural sourcing process only yields about two or three cannabinoids that can be derived in adequate quantities for research, while the rest of the cannabinoid compounds only manifest themselves in trace amounts that are not accessible through extraction from plants.

InMed’s biosynthesis method is can reduce the costs and time required to manufacture cannabinoid compounds that are pharmaceutically active. It is also capable of manufacturing not just some but all naturally occurring cannabinoids.

InMed is effectively bringing cannabis-based drug development into a new era, shaking up the established, agriculture-based mentality of “plant, grow, harvest, extract and purify” that has long been the norm in the area of manufacturing raw cannabinoid material.

The benefits of InMed’s novel approach are several and include:

Substantial cost savings in comparison to traditional agricultural methods
Easier path to scale-up and systems optimization
Superior production, purification, quality control as compared to agricultural approaches and better structural integrity in comparison with other chemical manufacturing practices
Ability to access minor cannabinoids for which plant-based extraction methods are currently economically unfeasible
InMed recently announced a provisional patent application filing for this proprietary cannabinoid manufacturing biosynthesis program—the first of many to come (http://nnw.fm/Z30dH). Once this inaugural patent application is converted into an international Patent Cooperation Treaty (PCT) application and is pursued on a global scale in important jurisdictions, InMed will have significant commercial protection for its biosynthesis program. The company plans to actively convert this initial patent filling and subsequent provisional patents into national-stage filings in all major commercial jurisdictions.

In terms of InMed’s internal drug development abilities, a recent press release from the company (http://nnw.fm/EZ0Gk) validates its capability to conduct a broad array of drug development activities that are crucial to obtaining eventual FDA approval for cannabinoid-based drugs. As discussed in the press release, InMed has successfully and consistently biosynthesized a pharmaceutical-grade cannabinoid using its novel E. coli-based system; packaged the cannabinoid as a nanoparticle; formulated a cannabinoid drug candidate into a novel, tissue-specific delivery vehicle; and confirmed drug delivery and diffusion into a target tissue.

The press release announced the results of a study co-sponsored by InMed and the University of British Columbia, which is, to the company’s knowledge, the very first study to ever report hydrogel-mediated cannabinoid nanoparticle delivery to the eye. This resulted in bolstered drug uptake through the cornea and lens. Ordinary ocular formulations, like eyedrops, are almost instantly washed away following administration because of blinking. In the study, however, InMed’s proprietary hydrogel delivery method demonstrated distinctive rheological characteristics that enabled it to form a thin, uniform coating over the cornea through blinking. The gel-like “lens” that was created over the cornea held the drug in place, allowing trans-corneal absorption of the drug to occur. The drug was then able to diffuse within the eye. The overall drug delivery achieved through this hydrogel nanoparticle formulation was three times higher than the control formulation.

“Importantly, this study offers further validation of InMed’s capabilities in moving the science of cannabinoid pharmaceuticals forward,” InMed President and CEO Eric A. Adams said in the press release. “Results like this, combined with our expanding patent portfolio and list of publications, on-going R&D, and renowned scientific team and collaborators demonstrates our depth of know-how and supports our trajectory to becoming an industry leader.”

InMed’s drug pipeline – developed using its biosynthesis process – currently includes two products: INM-085 for the treatment of glaucoma and INM-750 for the treatment of epidermolysis bullosa. This pipeline is founded on the company’s ability to produce its own pharmaceutical-grade cannabinoids for use in its products, which enables InMed to manage the entire drug development cycle. Using bioinformatics—a proprietary, computer-based drug/disease targeting platform developed by InMed—the company is also able to identify novel cannabinoids that could be utilized in targeting specific diseases. InMed can then biosynthesize those cannabinoids for product development.

This groundbreaking work is not only helping InMed toward overcoming drug approval barriers but could also have a huge impact on the efforts of other drug development companies within the cannabis sector that are striving to create cannabinoid-based therapies to treat various medical conditions.

InMed’s ability to consistently manufacture pharmaceutical-grade cannabinoids demonstrates the company’s favorable cost-savings and quality aspects compared with traditional cannabis producers. While such producers are working to meet the demands of biotech companies, which are, in turn, striving to satisfy regulatory standards, these producers may face many challenges.

One of the biggest marijuana growers in the world is Canopy Growth Corp. (TWMJF), which operates more than half-a-million square feet of production space. Despite its size and market domination, Canopy is dependent on significant capital and large parcels of land and is also handicapped by huge operating costs and the typical quality control issues seen with agricultural operations.

Another large producer, Aurora Cannabis (TSX: ACB) (OTCQX: ACBFF) operates a 55,200-square-foot cultivation and harvesting facility in the Rocky Mountains, and the company is in the process of adding an additional 840,000 square feet across two other sites in Canada. Aurora owns a 19.9% stake in the first Australian company licensed to cultivate and conduct research on medical cannabis, and it owns a leading Germany-based wholesale importer, exporter and distributor of medical cannabis. In January 2017, Aurora announced a Type II recall of its products, as some of its marketed offerings contained “residual levels of myclobutanil and/or bifenazate that exceed any of the levels permitted in food production for these two pesticides.”

Aphria (TSX: APH) (OTC: APHQF), a producer of medical-grade cannabis as well as capsules, vaporizers and orally-administered cannabis oil droppers, initiated a Type III recall of its own in March 2017 due to mislabeling of the delta-9-tetrahydrocannabidiol (THC) content of some of its products.

The obstacles faced by cannabis cultivators and the subsequent disadvantages to the drug development companies that rely on them attest to the importance of the revolutionary biosynthesis process InMed has pioneered. Despite continued federal restrictions on cannabis research and cultivation in the U.S., InMed’s innovations have the potential to help biotechs clear the hurdles and create biosynthesized cannabinoid-based pharmaceutical products of unparalleled consistency and quality required to meet the FDA’s standards. Additionally, the ability to manufacture every type of cannabinoid, which is made possible by InMed’s process, is poised to be one of the most exciting innovations the medical cannabis sector has seen.

For more information on InMed Pharmaceuticals, please visit: InMed Pharmaceuticals, Inc. (CSE: IN)
The QualityStocks Daily Newsletter http://Newsletter.QualityStocks.net

The QualityStocks Daily Blogs http://Blog.QualityStocks.net

Please read FULL Compensation Disclosures and other disclaimers at http://www.qualitystocks.net/disclaimer.php
QualityStocks
Site Admin
 
Posts: 1123
Joined: Mon May 21, 2007 7:58 pm
Location: Scottsdale, AZ

Re: InMed Pharmaceuticals, Inc. (IMLFF)

Postby QualityStocks » Wed Nov 15, 2017 5:56 pm

Innovation Drives Value for Leading Cannabis Biotechs

NetworkNewsWire Editorial Coverage: The medicinal cannabis market is expected to reach almost US$56 billion by 2025, according to a report by Grand View Research (http://nnw.fm/rXx0Z), driven in part by demand for therapeutic applications of cannabinoid-based drugs for pain relief, suppression of nausea and appetite stimulation, as well as for symptomatic treatment of diseases such as glaucoma, cancer and multiple sclerosis. As an increasing volume of scientific research leans toward the efficacy of cannabis-based drugs, innovative biotech companies are advancing their R&D to develop therapeutic candidates that envelop the potential health benefits of the marijuana plant. One such company is InMed Pharmaceuticals, Inc. (CSE: IN) (OTCQB: IMLFF) (IMLFF Profile), which has several cannabinoid-based drug candidates in its pipeline. The company has also developed a proprietary and groundbreaking technology for the biosynthesis of all 90+ cannabinoids via an innovative process that enables a wide spectrum of drug development activities in-house, from drug manufacture to novel, tissue-specific formulation and all clinical and regulatory work. Though currently valued at only US$81 million, InMed’s capabilities position it among the ranks of larger biotechs with important innovations in this industry, including GW Pharmaceuticals plc (NASDAQ: GWPH), Zynerba Pharmaceuticals, Inc. (NASDAQ: ZYNE), Cara Therapeutics, Inc. (NASDAQ: CARA) and INSYS Therapeutics, Inc. (NASDAQ: INSY).

Extracting cannabinoids for medicinal applications using an agriculture-based model involves a lengthy, expensive and labor-intensive process of planting, growing, harvesting, extracting and purifying. To avoid the shortcomings of an agricultural approach, several biotechs have turned to chemical processes to produce synthetic cannabinoids that can deliver consistent quality, thereby overcoming some of these concerns and increasing their prospects of gaining FDA approval. However, synthetic production can be expensive and can present potential safety issues. It is difficult to synthesize compounds that are identical to their natural counterparts, and the slightest structural variations can affect the quality and safety of the finished product.

While other biotech companies instead favor partnerships with pharmaceutical raw material suppliers for their cannabinoid supply, InMed Pharmaceuticals (OTCQB: IMLFF) (CSE: IN) utilizes its proprietary biosynthesis process to manufacture any of the 90+ individual cannabinoids found in cannabis. The company’s computer-based platform bolsters this production capability by using bioinformatic algorithms to match individual cannabinoids to specific diseases, thereby identifying potential therapeutic targets for its drug development programs.

InMed has been utilizing this bioinformatics approach for several years now. The platform enables the company to assess the interaction of individual cannabinoids with genes, target receptors, proteins and other criteria to measure suitability as active ingredients to target diseases. The output from the bioinformatics analysis can then be rapidly and cost-effectively validated in tissue and disease-specific in vitro and in vivo experimentation. Once confirmed in these bench-top experiments, the individual cannabinoids can then be manufactured at large scale using InMed’s proprietary biosynthesis system.

In short, InMed has the ability to:

Identify which cannabinoids have potential to treat specific diseases
Manufacture the desired pharmaceutical-grade cannabinoid at >95% purity, with identical structures to cannabinoids found in nature, with no pesticide residue; and
Formulate the cannabinoid drug candidate into a tissue-specific pharmaceutical product for advanced preclinical and clinical testing.
This innovation covers a broad spectrum of the drug development process without the need to create synthetic cannabinoids or rely on the quantity and quality of other cannabis growers.

InMed currently has two advanced candidates in its development pipeline. INM-750 is being developed for the treatment of epidermolysis bullosa (EB) and includes multiple cannabinoids as active ingredients. EB is a rare genetic disease with a very high unmet medical need and no currently approved treatments. INM-750 is being developed for topical application to regulate disease activity and alleviate the symptoms of EB. INM-085 is being development as a therapy for glaucoma, to be delivered as a hydrogel which can be administered once a day directly to intraocular pressure (http://nnw.fm/2EIBu). The estimated combined market potential of these two candidates is $6 billion per year.

InMed’s innovative approach to bioinformatics and biosynthesis is groundbreaking, and the company has already filed a provisional patent to protect its cannabinoid biosynthetic process.

InMed is currently working on scaling up its manufacturing capability, pivoting from the success of its proprietary laboratory-based systems. To assist with its advancing position in the market, InMed engaged as a consultant Ben Paterson, P.E., a professional engineer with extensive experience in the development of purification and manufacturing processes in the pharmaceutical industry (http://nnw.fm/9Bzoh).

Having pioneered the manufacture of cannabinoids, InMed is well positioned to maximize partnership activities by assisting biotechs and other companies – such as GW Pharmaceuticals (NASDAQ: GWPH) – with their cannabis-based drug programs. GW Pharmaceuticals is a world leader in the research and development of plant-based cannabinoid therapeutics, with a primary focus on the treatment of neurological conditions. Valued at more than US$2.5 billion, the company commercialized the world’s first cannabinoid-based drug for the treatment of spasticity caused by multiple sclerosis. Its leading development candidate is a formulation for the treatment of childhood-onset epilepsy disorders like Lennox-Gastaut syndrome and Dravet syndrome. On October 30, GW announced that it had completed its rolling submission of a new drug application to the Food and Drug Administration (FDA). The company also has several other product candidates in development for treating glioma and schizophrenia.

Zynerba Pharmaceuticals (NASDAQ: ZYNE) focuses its research efforts into developing synthetic cannabinoid therapeutics using a transdermal delivery mechanism. It has two products in development: ZYN001 – a THC-based formulation for pain relief in patients with fibromyalgia and peripheral neuropathic indications, and ZYN002 – an innovative and patented gel, which contains the non-psychoactive cannabidiol (CBD) as an active ingredient, for transdermal delivery to patients with osteoarthritis and Fragile X syndrome. Zynerba’s market valuation is over US$172 million.

Connecticut-based Cara Therapeutics (NASDAQ: CARA) has a market cap of US$400 million. The company has five product candidates in development, including a cannabinoid-based product, focusing on acute and chronic pain relief and the treatment of pruritus. Its proprietary formulations target the body’s peripheral nervous system. Medications that are available to treat these conditions typically have undesirable side effects, and initial trials of some of these candidates have demonstrated efficacy for both conditions without adverse reactions. The company’s most advanced opioid drug candidate, CR845, has been tested in phase 2 trials on patients undergoing laparoscopic hysterectomy or bunionectomy procedures with good results in pain reduction and the reduction of opioid-related side effects.

The improvement of patient care by delivering cannabinoid-based therapies for unmet patient needs is the mission of INSYS Therapeutics’ (NASDAQ: INSY), which is valued at US$380 million. The company markets a fentanyl sublingual spray, called Subsys®, for the relief of pain associated with cancer. Since 2014, Subsys® has achieved a market share of 48 percent of prescription fentanyl products. INSYS is also developing Syndros®, a synthetic THC product for the second-line treatment of nausea induced by chemotherapy and AIDS-related weight loss.

The rapidly emerging cannabis-based drug market is set for significant growth over the next few years as regulatory restrictions are eased and more companies are licensed. The innovation shown by these companies to date is what is needed to leverage market demand.

For more information on InMed Pharmaceuticals, visit InMed Pharmaceuticals, Inc. (OTCQB: IMLFF) (CSE: IN)
The QualityStocks Daily Newsletter http://Newsletter.QualityStocks.net

The QualityStocks Daily Blogs http://Blog.QualityStocks.net

Please read FULL Compensation Disclosures and other disclaimers at http://www.qualitystocks.net/disclaimer.php
QualityStocks
Site Admin
 
Posts: 1123
Joined: Mon May 21, 2007 7:58 pm
Location: Scottsdale, AZ

Re: InMed Pharmaceuticals, Inc. (IMLFF)

Postby QualityStocks » Thu Nov 16, 2017 7:47 pm

NetworkNewsBreaks – InMed Pharmaceuticals, Inc. (CSE: IN) (OTCQB: IMLFF) Presenting at Cannabis-Based Science Medicine Conference

InMed Pharmaceuticals (CSE: IN) (OTCQB: IMLFF) this morning said that it will be presenting twice at the Biopharma Forum on 'Cannabis-Based Science & Medicine' conference. The company will present on Thursday, November 30 and Friday, December 1 at the conference taking place in Denver, CO. The company’s chief scientific officer, Dr. Sazzad Hossain, will be presenting a lecture titled "Epidermolysis to Glaucoma - Identifying Pathology Candidates for Cannabis-Based Treatments." Among other areas of interest, the lecture will shine a light on InMed’s methods of identifying disease targets for cannabinoid compound treatments.
The QualityStocks Daily Newsletter http://Newsletter.QualityStocks.net

The QualityStocks Daily Blogs http://Blog.QualityStocks.net

Please read FULL Compensation Disclosures and other disclaimers at http://www.qualitystocks.net/disclaimer.php
QualityStocks
Site Admin
 
Posts: 1123
Joined: Mon May 21, 2007 7:58 pm
Location: Scottsdale, AZ

Re: InMed Pharmaceuticals, Inc. (IMLFF)

Postby QualityStocks » Tue Dec 05, 2017 6:16 pm

Purified Cannabinoids Open New Opportunities in Pain Management

NetworkNewsWire Editorial Coverage: As more Canadians than ever suffer chronic pain, the chase is on to find novel therapeutic approaches to effectively manage their conditions. In fact, BMC Public Health estimates that 20% of adults on a global level suffer from chronic pain while 10% are newly diagnosed every year. In Canada, chronic pain affects 1.5 million people. As national and worldwide numbers in pain diagnoses continue to rise, innovators in the cannabis industry are developing promising therapies to address this growing market. InMed Pharmaceuticals, Inc. (CSE: IN) (OTCQB: IMLFF) (IMLFF Profile), Aurora Cannabis, Inc. (OTCQX: ACBFF) (TSX: ACB), Canopy Growth Corp. (OTC: TWMJF) (TSX: WEED), Aphria, Inc. (OTCQB: APHQF) (TSX: APH) and Isodiol International, Inc. (OTCQB: ISOLF) (ISOL: CNX) each play a unique role in the increased acceptance and promise of medical marijuana and its purified derivatives for pain management and other medical needs.

The medical cannabis industry in Canada alone has gained impressive traction since its legalization in 2001, and industry statistics show increases from CAD$49 million in 2015 to projections of over $1.1 billion by the year 2020. Scientists, doctors, and pharmaceutical companies alike attribute this never-before seen rise in the market to consumer confidence in the therapeutic qualities of cannabis-derived products.

As consumer acceptance continues to propel demand to unprecedented levels, companies such as InMed Pharmaceuticals (CSE: IN) (OTCQB: IMLFF) are making waves in the advancement of cannabinoid compounds as a medical solution in pain management and other indications. The biopharmaceutical company focuses its efforts in the development of novel therapies surrounding the extensive pharmacology of cannabinoids (cannabis’ bioactive compounds) and innovative drug delivery systems.

Canadian marijuana companies are leading the way on a global scale by establishing high standards in the growing and cultivation of quality products. InMed is taking a very unique approach by focusing on a proprietary cannabinoid manufacturing process that sets it apart as a catalyst of improvement in the availability of pharmaceutical-grade cannabinoids.

The company’s proprietary biosynthesis process has the ability to combine the intrinsic safety and efficacy of natural drug structures with the convenience, control and quality of a laboratory-based manufacturing process. Aside from significant cost savings, this process enables enhanced production, purification, and quality control compared to the typical grow-harvest-extract-purify methods employed by other companies. Notably, InMed’s biosynthesis system allows the manufacturing of all of the 90+ naturally occurring cannabinoids at a relatively low cost, regardless of how rare each compound may be in nature.

Using its exclusive process in a controlled laboratory setting, InMed can manufacture cannabinoid compounds that are identical to those found in nature without the difficult, expensive and time-consuming challenges of planting, growing and harvesting cannabis then laboriously extracting the individual cannabinoids for medical use. It also completely eliminates any need for fertilizers or pesticides.

Earlier this year, InMed filed a provisional U.S. patent for its pain management program (http://nnw.fm/6GHOq). The program, which includes the INM-405 therapy, along with other similar compositions of cannabinoid-based topical therapies for the treatment of pain, is an important step to not only protecting the company’s commercial and intellectual property, but also in establishing themselves as a major player in the pain management industry.

While there are numerous pharmaceutical products to treat both acute and chronic pain, the increase in the number of prescriptions for opioids has led to concerns of addiction, damaging side effects, and death. According to the U.S. Centers for Disease Control and Prevention, drug overdose deaths continue to increase in the United States, with the majority (more than 60%) involving an opioid. Since 1999, the number of overdose deaths involving opioids (including prescription opioids and heroin) quadrupled, as have the number of prescriptions for opioids, yet there has been no increase in the amount of pain reported in the general population. Thus, there is a need to find alternatives to treat chronic and severe pain that are non-addictive and have limited side effects. InMed is researching the potential of non-THC (tetrahydrocannabinol, a psychoactive ingredient in cannabis) cannabinoids to treat pain using a proprietary topical formulation.

InMed’s advancements can be attributed to the company’s proprietary bioinformatics assessment tool, which is able to identify which cannabinoids can potentially target individual diseases (including pain).

As Canada’s medical marijuana industry continues to grow at a rapid rate, licensed producers of medical cannabis crops and pharmaceutical-grade cannabinoids are placing special emphasis on areas such as consistency and efficiency in order to keep up with market demands and provide easier product access, especially surrounding treatable conditions like pain management.

Aurora Cannabis (OTCQX: ACBFF) (TSX: ACB), award-winning contributor to Canada’s legal medical cannabis industry, provides top-quality cannabis to patients through laboratory tested products, culture-minded cultivators, and a network of highly educated doctors in the cannabis industry. It is with these quality processes that they help to remove barriers of access.

Every patient’s symptoms and situation is completely unique, and so should be the care they receive. Aphria (OTCQB: APHQF) (TSX: APH), a producer of high-quality, pure and safe cannabis, combines superior patient care with products that are safe and consistent, with a commitment to exceeding baseline government and regulatory body standards for medical cannabis products. When it comes to medicine, adequate is simply not good enough. Aphria’s priorities lie within consistency, safety and efficacy.

Others, such as Canopy Growth (OTC: TWMJF) (TSX: WEED), is leading the world as a diversified cannabis company through its partnerships with leading names in the sector. The company’s core brands – Tweed, Spectrum Cannabis and Bedrocan Canada – don’t just sell quality cannabis and create meaningful customer relationships, they facilitate trusted conversations surrounding cannabis, simplify stakeholder outreaches, healthcare interactions, and patient education through color-identifying spectrum labeling, as well as a commitment to research, refinement, and licensing of medicinal cannabis products.

Companies such as Isodiol International (OTCQB: ISOLF) (ISOL: CNX) take their research and development a step further, focusing on the phytoceutical optimization of cannabinoids to maximize the bioactivity in the human body, allowing a more targeted treatment of specific health conditions. As an industry leader in the development and manufacturing of consumer products and raw ingredients derived from cannabis, Isodiol has pioneered many of the first hemp derivatives including micro-encapsulation for topical products, a 99% pure crystalline power, and nanotechnology for use in beverage and food applications.

Indeed, the overall support for medical cannabis appears to be on the rise, with an overwhelming amount of reports revealing high success in pain reduction as well as the reduction of other medication needs in the presence of medical marijuana and cannabinoid use. InMed Pharmaceuticals appears to be tackling these breakthroughs in conventional medication with its own scientifically derived advancements in the biosynthesis process. These advancements present a unique opportunity for those interested in investing in the rapid pace of the cannabinoid pharmaceutical and pain management industries.

For more information on InMed Pharmaceuticals, visit InMed Pharmaceuticals, Inc. (OTCQB: IMLFF) (CSE: IN)
The QualityStocks Daily Newsletter http://Newsletter.QualityStocks.net

The QualityStocks Daily Blogs http://Blog.QualityStocks.net

Please read FULL Compensation Disclosures and other disclaimers at http://www.qualitystocks.net/disclaimer.php
QualityStocks
Site Admin
 
Posts: 1123
Joined: Mon May 21, 2007 7:58 pm
Location: Scottsdale, AZ

Re: InMed Pharmaceuticals, Inc. (IMLFF)

Postby QualityStocks » Wed Dec 06, 2017 5:28 pm

Advanced Biosynthesis Setting New Standards for Cannabinoid-based Pain Management

NetworkNewsWire Editorial Coverage: Cannabis derivatives have been used medicinally around the world for millennia. However, concerns surrounding potential dangers and abuse of marijuana’s psychoactive component THC (tetrahydrocannabinol) led to the banning of medicinal cannabis early in the 20th Century. Recent scientific studies, however, have given new credence to the wisdom from millennia ago and have scientifically proven the medical efficacy of certain cannabinoids for developing new approaches to treating diseases with high unmet medical needs. Global scientists, researchers, and biopharmaceutical companies are now focused on cannabinoids that have therapeutic potential. One pioneering biopharmaceutical company, InMed Pharmaceuticals, Inc. (CSE: IN) (OTCQB: IMLFF) (IMLFF profile), has triggered a paradigm shift in discovering potential breakthrough cannabinoid-based therapies. InMed Pharmaceuticals utilizes its robust, proprietary biosynthesis process to isolate and create pharmaceutical grade, bio-identical cannabinoids in the laboratory where it can cost-effectively manufacture any of the 90+ cannabinoid compounds at pharmaceutical-grade (greater than 95 percent) purity. InMed also employs its proprietary bioinformatics assessment tool to determine therapeutic approaches for specific diseases by analyzing pharmaceutical and cannabinoid structures to identify associations between approved pharmaceuticals and particular cannabinoids to attain parallel biological responses. The company’s combination of comprehensive proprietary processes sets it apart from others trying to compete in this arena. Other companies on the trail of new cannabinoid medicines and drug classes include GW Pharmaceuticals (NASDAQ: GWPH), Zynerba Pharmaceuticals (NASDAQ: ZYNE), Cara Therapeutics, Inc. (NASDAQ: CARA) and Axim Biotechnologies (OTC: AXIM).

Other biopharmaceutical companies may produce cannabinoids in the laboratory using chemical synthesis, but there’s a litany of drug development efforts with synthetic molecules that have failed. The proprietary biosynthesis process used by InMed Pharmaceuticals, Inc.’s (CSE: IN) (OTCQB: IMLFF) is unique. Producing cannabinoids that are identical to naturally occurring compounds is transformative for drug development. By using its proprietary process, InMed is able to manufacture exact cannabinoid replicas for use in research. This novel breakthrough gives InMed scientists the ability to manufacture all 90+ cannabinoid compounds identical to those found in nature and the ability to consistently, reliably and accurately test efficacy and safety. In addition, InMed’s cost-effective biosynthesis process enhances production, purification, and quality control as opposed to other chemical manufacturing methods. InMed’s biopharmaceutical approach to the production of pharmaceutical grade, bio-identical cannabinoids is disruptive in the development of pharmaceutical cannabinoids for research and drug creation. The company’s high-yield manufacturing process also provides simpler scale-up and systems optimization, as well as the production of minor cannabinoids that are economically impractical to extract from plant sources.

To protect this invaluable asset, InMed has filed a provisional patent for the biosynthesis of cannabinoids (http://nnw.fm/RPTj0), and the company continues to use the technology to expand its pipeline for treating a variety of medical conditions.

InMed’s cannabinoid biosynthesis process is complemented by its bioinformatics drug and disease targeting tool. Bioinformatics is a high-efficiency, computer-assisted approach to predicting the therapeutic potential and medicinal properties of individual cannabinoids against particular medical conditions. InMed’s proprietary approach applies comprehensive algorithms to integrate the data from various bioinformatics databases, including a vast database of the chemical structures of approved pharmaceuticals, with InMed’s proprietary cannabinoid database and know-how.

Study results published earlier this year by InMed in the European Journal of Pain (NR July 27, 2017) highlighted the topical application of cannabinoids to successfully treat peripheral pain, and on October 17, 2017 the company issued an update on its cannabinoid-based pain drug program (http://nnw.fm/o8rPL) to include the potential of non-THC cannabinoids for pain management.

Pre-clinical results in the development of the company’s INM-405 candidate for the treatment of pain suggest that peripheral application of certain cannabinoid compounds, alone or in combination, is effective in the treatment of craniofacial muscle pain disorders such as temporomandibular disorders (TMD) and trigeminal neuralgia (TN) — without any observed central nervous system side effects.

TN in particular is known for symptoms involving intense and uncontrollable face and jaw spasms, causing pain that is so severe it has been nicknamed “the suicide disease.” It is estimated that 12 new cases of TN occur per 100,000 persons every year, according to the National Institute of Neurological Disorders and Stroke. Sufferers have found some relief smoking marijuana, but must do so frequently and are subject to protracted psycho-activity caused by THC. InMed recognizes the need and market opportunity for non-opioid alternatives to treat chronic and severe pain with limited side effects.

InMed has since filed a provisional patent application for INM-405 and other unique compositions as cannabinoid-based topical therapies for the treatment of pain (http://nnw.fm/K0MRo), noting the need for therapies centered on specific non-psychoactive cannabinoids.

“There remains a significant need in the field of analgesia for a product that can treat pain via a topical route of administration, which would reduce systemic exposure and any associated side effects,” Dr. Sazzad Hossain, chief scientific officer of InMed Pharmaceuticals and a co-inventor on the patent, stated in the October 3 press release. “InMed’s focus on non-psychoactive cannabinoids further reduces concerns regarding addiction, a key concern in pain management.”

Pain management represents only a sliver of the market potential for InMed’s pipeline as it relates to broader demand for cannabinoid-based therapies. The company’s comprehensive pharmaceutical approach to cannabinoid drug development may likely set a new standard in cannabinoid pharmacology.

As evidenced by the size and application of such innovations by other biotech leaders, the market opportunity for InMed could be substantial.

One of the most recognized names in cannabinoid medicine is GW Pharmaceuticals plc (NASDAQ: GWPH). Researching cannabinoids since 1998, the company is focused on developing and commercializing therapeutics from its cannabinoid product platform across a range of disease areas. GW’s lead cannabinoid product candidate is a liquid formulation of pure plant-derived cannabidiol (CBD). The company has established industry leadership through the early development of plant-derived therapeutics, drug discovery processes, manufacturing and regulatory expertise, and a portfolio of intellectual properties. The company developed the world’s first prescription cannabis-derived medicine, Sativex, which is approved for use in countries outside of the United States for the treatment of multiple sclerosis spasticity. GW’s lead cannabidiol product candidate, Epidiolex, is in development for the treatment of a number of rare childhood-onset epilepsy disorders.

Zynerba Pharmaceuticals (NASDAQ: ZYNE) is a clinical-stage specialty pharmaceutical company dedicated to developing and commercializing innovative pharmaceutically produced transdermal cannabinoid treatments for patients with high unmet medical needs. Engaged in the research and development of cannabinoid drugs, the company has developed a synthetic transdermal cannabinoid product in the form of a gel that enables compounds to pass through the skin and into the blood supply. A skin patch is also available. Zynerba’s development pipeline includes patent-protected pharmaceutically-produced transdermal cannabinoid products. The company has been working on cannabinoid-based treatments for Fragile X syndrome, epilepsy, osteoarthritis, fibromyalgia and peripheral neuropathic pain.

Cara Therapeutics, Inc. (NASDAQ: CARA) is a clinical-stage biotech company looking to change how pain is treated. Its portfolio includes opioid-based products, anesthetic-based drugs, and analgesics that seek to alleviate itch and pain. Cara is developing a new class of medicine called Kappa Opioid Receptor Agonists (KORAs). KORAs target a completely different receptor in the body, the kappa opioid receptor, to treat pain in a fundamentally new way. The company’s lead pipeline product, CR845, is a peripherally acting type of KORAs. To date, CR845 has shown in phase II clinical trials promising pain relief without many of the traditional side effects of opioids and NSAIDs.

Axim Biotechnologies (OTCQB: AXIM) engages in the research, development, and production of pharmaceutical, nutraceutical, and cosmetic products. It focuses on the treatment of pain, spasticity, anxiety, and other medical disorders with the application of cannabinoid based products. Research in the use of molecularly modified cannabinoids as neuroprotectants is currently being conducted and the use of industrial hemp-derived CBG-containing (cannabigerol) formulations for dermatological applications is also being researched. The company’s MedChewRx™ is undergoing clinical studies. The company’s chewing gum is the first preparation of its kind, under study for not only its proprietary active pharmaceutical ingredients but also for unique additional benefits via the act of mastication.

The medicinal wisdom from millennia ago is being borne out by the science of today. There’s immense promise for patients in medicinal cannabis therapies and incredible economic opportunity for companies like InMed using innovative technology with the goal of bringing blockbuster cannabis-based drugs to market.

For more information on InMed Pharmaceuticals, please visit: InMed Pharmaceuticals, Inc. (CSE: IN) (OTCQB: IMLFF)
The QualityStocks Daily Newsletter http://Newsletter.QualityStocks.net

The QualityStocks Daily Blogs http://Blog.QualityStocks.net

Please read FULL Compensation Disclosures and other disclaimers at http://www.qualitystocks.net/disclaimer.php
QualityStocks
Site Admin
 
Posts: 1123
Joined: Mon May 21, 2007 7:58 pm
Location: Scottsdale, AZ

Re: InMed Pharmaceuticals, Inc. (IMLFF)

Postby QualityStocks » Wed Dec 06, 2017 6:08 pm

NetworkNewsBreaks – InMed Pharmaceuticals, Inc. (CSE: IN) (OTCQB: IMLFF) Featured in Visual Capitalist Company Spotlight

Pre-clinical stage biopharmaceutical company InMed Pharmaceuticals, Inc. (CSE: IN) (OTCQB: IMLFF) was recently highlighted in a company spotlight article by Visual Capitalist. The article features an infographic that breaks down the company’s development of novel cannabinoid-based therapies from start to finish. Among other areas of interest, Visual Capitalist provided an in-depth look into InMed's Bioinformatics assessment tool, Biosynthesis cannabinoid manufacturing process, and drug pipeline of new cannabinoid treatments.
The QualityStocks Daily Newsletter http://Newsletter.QualityStocks.net

The QualityStocks Daily Blogs http://Blog.QualityStocks.net

Please read FULL Compensation Disclosures and other disclaimers at http://www.qualitystocks.net/disclaimer.php
QualityStocks
Site Admin
 
Posts: 1123
Joined: Mon May 21, 2007 7:58 pm
Location: Scottsdale, AZ

Re: InMed Pharmaceuticals, Inc. (IMLFF)

Postby QualityStocks » Mon Dec 11, 2017 6:33 pm

NetworkNewsBreaks – InMed Pharmaceuticals, Inc. (CSE: IN) (OTCQB: IMLFF) Utilizes Proprietary Advanced Biosynthesis Process to Develop Cannabinoids-based Therapies

InMed Pharmaceuticals (CSE: IN) (OTCQB: IMLFF) remains focused on discovering potential breakthrough cannabinoid-based therapies by utilizing its proprietary cannabinoid biosynthesis process and its bioinformatics drug and disease targeting tool. An article discussing this reads: “Other biopharmaceutical companies may produce cannabinoids in the laboratory using chemical synthesis, but there’s a litany of drug development efforts with synthetic molecules that have failed. The proprietary biosynthesis process used by InMed Pharmaceuticals, Inc.’s (CSE: IN) (OTCQB: IMLFF) is unique. Producing cannabinoids that are identical to naturally occurring compounds is transformative for drug development. By using its proprietary process, InMed is able to manufacture exact cannabinoid replicas for use in research. This novel breakthrough gives InMed scientists the ability to manufacture all 90+ cannabinoid compounds identical to those found in nature and the ability to consistently, reliably and accurately test efficacy and safety. In addition, InMed’s cost-effective biosynthesis process enhances production, purification, and quality control as opposed to other chemical manufacturing methods. InMed’s biopharmaceutical approach to the production of pharmaceutical grade, bio-identical cannabinoids is disruptive in the development of pharmaceutical cannabinoids for research and drug creation. The company’s high-yield manufacturing process also provides simpler scale-up and systems optimization, as well as the production of minor cannabinoids that are economically impractical to extract from plant sources.”
The QualityStocks Daily Newsletter http://Newsletter.QualityStocks.net

The QualityStocks Daily Blogs http://Blog.QualityStocks.net

Please read FULL Compensation Disclosures and other disclaimers at http://www.qualitystocks.net/disclaimer.php
QualityStocks
Site Admin
 
Posts: 1123
Joined: Mon May 21, 2007 7:58 pm
Location: Scottsdale, AZ

Re: InMed Pharmaceuticals, Inc. (IMLFF)

Postby QualityStocks » Tue Dec 12, 2017 5:37 pm

The Therapeutic Potential of Pharmacologically Active Cannabinoids

NetworkNewsWire Editorial Coverage: The discovery of the human body’s endocannabinoid system in the early 1990s led to a surge of new drug development activity to address multiple maladies and identify new ways to treat serious diseases. The pharma industry’s predominant focus has been on the most recognized and easiest-to-isolate plant-sourced cannabinoids THC (tetrahydrocannabinol) and CBD (cannabidiol). Despite their potential therapeutic efficacy, plant-sourced cannabinoid therapies have complex development limitations that impede effective use. Beyond economic constraints on production, inherent problems exist in ensuring the quality, purity and consistency requisite for serious pharmaceutical drug development. But InMed Pharmaceuticals, Inc. (CSE: IN) (OTCQB: IMLFF) (IMLFF Profile) has initiated a scientific paradigm shift in discovering potential breakthrough cannabinoid-based therapies that advances far beyond basic cannabinoid production and the over-the-counter sales of oils and elixirs. The company’s proprietary biosynthesis process sets it apart from the operations of companies like Isodiol International, Inc. (OTCQB: ISOLF) (ISOL: CNX), as well as from other biotechs and growers in the cannabis industry who rely on the supply of leading cultivators like Canopy Growth Corp. (TSX: WEED) (OTC: TWMJF), Aurora Cannabis, Inc. (TSX: ACB) (OTCQB: ACBFF) and Aphria, Inc. (TSX: APH) (OTC: APHQF).

The human endocannabinoid system is one of the most important physiologic systems involved in general well-being. The human body naturally produces endocannabinoids, which bind to cannabinoid receptors present in the body where they act as chemical messengers between cells, tissues and organs. This innate biological system has been found to interact with the 90+ cannabinoids identified in the cannabis plant, leading to a wide range of pharmacological effects related to pain, inflammation, neurotransmission, stress, metabolism, appetite and several other body functions.

InMed Pharmaceuticals, Inc. (CSE: IN) (OTCQB: IMLFF) has a robust, proprietary biosynthesis process to manufacture pharmaceutical-grade (greater than 95% purity) cannabinoids using a cost-effective, laboratory-based process.

Biosynthesis is the preparation of biological molecules using catalysts derived from natural substances, which are then converted into other compounds. As an example, millions of diabetics use insulin produced via biosynthesis. InMed’s proprietary biosynthetic process produces cannabinoids that are identical to naturally occurring compounds and is transformative in ensuring the pharmaceutical standards for therapeutic cannabinoids. This novel breakthrough gives InMed the ability to bio-identically manufacture every cannabinoid compound found in nature and the ability to consistently, reliably and accurately test the compounds’ therapeutic efficacy and safety.

InMed employs a proprietary bioinformatics drug and disease-targeting tool in conjunction with its biosynthesis process. Bioinformatics is a high-efficiency, computer-assisted approach to predicting the therapeutic potential and medicinal properties of individual cannabinoids against particular medical conditions. InMed’s approach applies comprehensive algorithms to combine data from various bioinformatics databases with its proprietary cannabinoid database.

These systems give the company significant competitive advantage. To protect this invaluable asset, InMed has filed a provisional patent for the biosynthesis of cannabinoids (http://nnw.fm/RPTj0), using the process as a base to expand its pipeline of drug candidates. InMed’s current pipeline includes INM-750 to treat epidermolysis bullosa, a rare disease characterized by extremely fragile skin, with potential global market revenues estimated around US$1 billion per year; INM-085, in development to treat glaucoma, with global market potential of more than US$5 billion; and INM-405, which targets the US$36 billion-plus global market for pain therapy.

Study results published earlier this year by InMed in the European Journal of Pain (http://nnw.fm/8RbQF) highlighted the topical application of certain cannabinoids to successfully treat peripheral pain. Study results (http://nnw.fm/4nCmZ) suggest InMed’s approach may prove valuable in the treatment of severe craniofacial muscle pain disorders and there’s reason to believe similar benefits for treating osteoarthritis may been seen.

In the latest market report published by Credence Research, Inc. (http://nnw.fm/pDKs0), the osteoarthritis treatment market was valued at US$5 billion in 2015. Despite medical advances, there remain significant unmet medical needs in treating osteoarthritis due to the absence of effective therapies for the chronic disease. Currently available treatment options don’t provide adequate pain relief, especially in the late stages of osteoarthritis, which has led to increased opioid abuse. As such, there is a real need to find non-addictive alternatives with limited side effects to treat chronic and severe pain, and InMed’s comprehensive pharmaceutical approach to cannabinoid drug development may prove to be the solution.

Many other companies are pursuing medicinal cannabinoids, mostly CBD, through horticultural cultivation. The process of planting, growing, harvesting, extracting and purifying the product is costly, inexact, inconsistent and unreliable. A recent study published in JAMA (http://nnw.fm/f9FAa) revealed that nearly 70% of CBD extracts from marijuana sold online are mislabeled, some had extra CBD, some less, and some contained hidden cannabinoids. Blind testing found that only about 31 percent of the extracts tested contained the amount of CBD listed on the label (within a 10% allowed variance).

InMed’s ability to consistently manufacture pharmaceutical-grade cannabinoids may prove to be a significant advantage over traditional cannabis growers.

Companies developing medicinal cannabinoids through traditional horticultural methods include Canopy Growth (TSX: WEED) (OTC: TWMJF), a diversified Canadian cannabis company offering distinct brands and curated cannabis varieties in dried, oil and capsule forms. Through its 665,000 square feet of licensed production, over 500,000 square feet of which is good manufacturing practice (GMP) certified. Canopy Growth and its affiliates plan to develop a production platform that would represent 3.2 million square feet of indoor and greenhouse production capacity, all operated with leading edge production, quality assurance procedures, value-added post processing, research and testing. Canopy Growth has established partnerships with recognized sector names in Canada and abroad, with interests and operations spanning seven countries and four continents. The company is dedicated to educating healthcare practitioners, providing consistent access to high-quality cannabis products, conducting robust clinical research, and furthering the public’s understanding of cannabis.

Through its wholly-owned subsidiary, Aurora Cannabis Enterprises Inc., Aurora Cannabis (TSX: ACB) (OTCQB: ACBFF) is a Canadian licensed producer of horticulturally grown medical cannabis. The company operates a 55,200-square-foot production facility in Alberta and a second 40,000-square-foot production facility in Quebec. The company is constructing an 800,000-square-foot production facility at the Edmonton International Airport, as well as a fourth facility in Lachute, Quebec, through its wholly-owned subsidiary Aurora Larssen Projects Ltd. Aurora holds about 19 percent of the issued shares in an extraction technology company, Radient Technologies Inc., and is in the process of completing an investment for up to 50.1 percent of Hempco Food and Fiber. Aurora also holds a 22.9 percent stake in Cann Group Limited, the first Australian company licensed to cultivate and research medical cannabis. Aurora owns Pedanios, a wholesale importer, exporter and distributor of medical cannabis in the EU.

One of Canada’s lowest-cost horticultural producers, Aphria (TSX: APH) (OTC: APHQF), cultivates, supplies and sells medical cannabis. Located in Leamington, Ontario, Aphria is powered by sunlight, allowing for some of the most natural growing conditions available. Aphria is committed to providing pharma-grade medical cannabis for superior patient care while balancing patient economics and returns to shareholders. Aphria’s medicinal cannabis is 100 percent greenhouse grown in natural sunlight and offers a patient care team to assist customers purchasing its THC and CBD products.

Isodiol International (CSE: ISOL) (OTC: ISOLF) (FSE: LB6A.F) is a market leader in pharmaceutical- and nutraceutical-grade phytochemical (plant-based) compounds, specializing in the manufacturing and development of phytoceutical consumer products. Isodiol is one of the world’s largest sources for phytocannabinoids and offers high-quality, bioactive products from seed to finished product. Isodiol is a pioneer in the cannabis industry for the commercialization of 99 percent-plus pure, bioactive pharmaceutical grade cannabinoids, micro-encapsulations and nanotechnology for high-quality consumable and topical skin care products. Isodiol’s growth strategy includes the development of over-the-counter and pharmaceutical drugs, expanding its phytoceutical portfolio and aggressively continuing its international expansion into Latin America, Asia, and Europe.

The discovery of the human endocannabinoid system and its interaction with cannabinoids to produce pharmacological modulation for pain, inflammation and other ailments may provide the long sought-after solutions to effectively treat pain inherent with osteoarthritis and other chronic and severe illnesses. There’s immense promise that pharmacological cannabinoids may soon provide relief for suffering patients and there’s an economic bonanza waiting for companies like InMed that aim to bring these blockbuster cannabis-based drugs to market.

For more information on InMed Pharmaceuticals, please visit: InMed Pharmaceuticals, Inc. (CSE: IN) (OTCQB: IMLFF)
The QualityStocks Daily Newsletter http://Newsletter.QualityStocks.net

The QualityStocks Daily Blogs http://Blog.QualityStocks.net

Please read FULL Compensation Disclosures and other disclaimers at http://www.qualitystocks.net/disclaimer.php
QualityStocks
Site Admin
 
Posts: 1123
Joined: Mon May 21, 2007 7:58 pm
Location: Scottsdale, AZ

Re: InMed Pharmaceuticals, Inc. (IMLFF)

Postby QualityStocks » Wed Dec 13, 2017 6:31 pm

Dangerous Opioid Side Effects Shift Market Focus to Cannabis for Chronic Pain

NetworkNewsWire Editorial Coverage: The $58.6 billion global market for pain management drugs is on track to hit upward of $77.1 billion by 2023 on a 4 percent CAGR. North America was the largest segment of this massive market last year, and opioids were the biggest driver of growth due to their efficacy in managing severe chronic pain. However, this efficacy is dramatically offset by the enormous economic cost of what is now officially a nationwide crisis. Opioid abuse, addiction and overdose deaths cost an estimated 2.8 percent of GDP in 2015 alone (over $504 billion) according to the Council of Economic Advisers. This escalating public health crisis has thrown a bright spotlight on new pain management alternatives void of addictive components and reduced adverse side effects. The need for alternatives like cannabinoid-based therapies is generating significant market interest for prospective solution developers such as InMed Pharmaceuticals, Inc. (CSE: IN) (OTCQB: IMLFF) (IMLFF profile), a preclinical-stage biopharmaceutical company focused on developing its pipeline of novel therapies based on the integration of the pharmacology of cannabinoids and innovative drug delivery systems. InMed’s approach to the therapeutic potential of cannabinoids is what differentiates it from others in the biotech space, such as GW Pharmaceuticals (NASDAQ: GWPH), Zynerba Pharmaceuticals (NASDAQ: ZYNE), Cara Therapeutics, Inc. (NASDAQ: CARA) and Axim Biotechnologies (OTC: AXIM).

While most cannabis-focused biotechs funnel their resources and time into the development of medicines using the two most common cannabinoids — tetrahydrocannabinol (THC) and cannabidiol (CBD) — InMed Pharmaceuticals, Inc.’s (CSE: IN) (OTCQB: IMLFF) proprietary biosynthesis process has demonstrated capabilities that allows the company to consistently manufacture all of the 90-plus naturally occurring cannabinoids in-house, eliminating the expenses of growing or buying cannabis plant matter to develop its pipeline of therapies (http://nnw.fm/dGPc0).

The company’s ability to create bio-identical, pharmaceutical-grade cannabinoids is a crucial differentiator that enables InMed to also address two primary challenges to the research and development of cannabinoids. Typically, the research of cannabinoids for the treatment of disease is marked by two factors: First, it is obstructed by the fact that these compounds occur in very low concentrations of the cannabis plant and second, it is limited by the exorbitant costs of isolating sufficient quantities of cannabinoids needed to conduct research.

InMed’s proprietary biosynthesis technology, however, is a game changer, placing the ability to extract high yields of minor cannabinoids within the realm of commercial viability and unprecedented medical research.

This is particularly key as the company advances its INM-405 candidate for the treatment of pain. Recent pre-clinical data from the company’s pain treatment program (http://nnw.fm/4ICzO) suggests that topical application of certain non-THC cannabinoid compounds is effective in treating peripheral pain in craniofacial muscle pain disorders.

This achievement builds on the company’s proof-of-concept study results published earlier this year in the European Journal of Pain, suggesting that THC could reduce masticatory muscle pain through the activation of peripheral cannabinoid receptors CB1 and CB2, which are primary targets in the human body for cannabinoid drugs.

As the need remains for non-addictive pain management alternatives with limited side effects, InMed continues to research the potential of non-THC cannabinoids to treat pain using a topical formulation. The company recently filed a provisional patent application in the United States for INM-405 and other unique cannabinoid-based topical therapies for the treatment of pain, recognizing that the significant unmet need for a topical analgesic without the typical systemic exposure and side effects represents a huge target.

InMed’s chief scientific officer and co-inventor on the patent, Dr. Sazzad Hossain, in a press release announcing the filing was keen to point out how InMed’s focus on non-psychoactive cannabinoids further reduces the entire industry’s prevailing concerns about addiction.

“There remains a significant need in the field of analgesia for a product that can treat pain via a topical route of administration, which would reduce systemic exposure and any associated side effects,” he stated (http://nnw.fm/xc4uV). “InMed’s focus on non-psychoactive cannabinoids further reduces concerns regarding addiction, a key concern in pain management.”

According to the Centers for Disease Control (“CDC”), more than 60,000 people in the United States were killed by drug overdoses in 2016, an increase of 22 percent compared to the year prior. Drug overdoses are expected to remain the leading cause of death in Americans under the age of 50, and the CDC report notes that synthetic opioids are leading to an uptick of drug-related deaths. The use of drugs such as fentanyl increased 72% from 2014-2015 (http://nnw.fm/pU2El).

In light of these statistics, the race is heating up for a way to curb the dramatic increase in the number of prescriptions for opioids. A topical cannabinoid product for pain management, particularly a non-THC based one, could be just the ticket.

InMed’s INM-405 patent cites a range of topically applied cannabinoids (alone or in combination) for the treatment of a variety of pain types ranging from muscle and nerve to arthritis-induced joint pain, providing for the company an opportunity to tap into the osteoarthritis market, which is expected to reach $3.5 billion by 2026, and the market for orofacial pain, pegged at $6 billion a year.

This approach not only represents a vastly preferable solution compared to orally administered pain relievers, it dovetails perfectly with InMed’s biosynthesis program to produce commercial quantities of cannabinoids for other candidates in is pipeline, which includes INM-750 for the treatment of Epidermolysis Bullosa (genetic condition characterized by fragile, blistering skin), and INM-085 for the treatment of the optic nerve-damaging, degenerative disease glaucoma.

As InMed focuses on scaling-up and commercializing this biosynthesis platform, the company has tapped leading cannabinoid researchers to assist with its progress. In September the company retained the consulting services of Ben Paterson, P.E., who has nearly four decades of experience in developing processes for pharmaceutical manufacturing and purification, including all facets of biosynthesis manufacturing and facility design (http://nnw.fm/Ug7Ok). Paterson was previously a senior engineering advisor with Eli Lilly and Company, where he spent 37 years, including 24 years in its biosynthesis division. InMed next named to its Scientific Advisory Board Dr. Mauro Maccarrone, professor and chair of biochemistry and molecular biology at Campus Bio-Medico, University of Rome (http://nnw.fm/3DYAn).

InMed’s ongoing development of its proprietary biosynthesis platform recently saw what the company believes to be two significant industry firsts (http://nnw.fm/S9H3z): a new and substantially more robust metabolic pathway capable of manufacturing the much-sought-after terpenoid family of cannabinoid precursors (diverse organic compounds typically in the form of aromatic oils), as well as the first production of fully assembled cannabinoids that are bio-identical to the 90-plus known plant-based cannabinoids.

This unique technological advantage not only gives InMed a serious leg up when it comes to cost-effectively producing the raw materials the company needs to advance its own pipeline, but could also have a major impact on other biotech companies developing cannabinoid-based therapeutics as well. This technology has the potential to become an industry standard when it comes to cost-effectively obtaining large quantities of the many different cannabinoids required by tomorrow’s breakthrough therapies.

GW Pharmaceuticals plc (NASDAQ: GWPH) is looking for a new drug application decision from the FDA on an orphan drug designated Epidiolex (purified, plant-derived cannabidiol) for Dravet syndrome and Lennox-Gastaut syndrome (epilepsies) by as early as the middle of 2018 (http://nnw.fm/rNVu6). The company is also prepping for European regulatory approval coming off a landmark publication in The New England Journal of Medicine, as well as key presentations at the American Academy of Neurology and American Epilepsy Society annual meetings. GW Pharmaceuticals is also advancing a number of additional clinical programs and could make good use of a cost-effective, robust and more articulable process for obtaining the raw materials that go into its indications.

Zynerba Pharmaceuticals (NASDAQ: ZYNE), developer of products like ZYN002, the first and only pharmaceutically made CBD formulated as a patent-protected permeation-enhanced gel, is another good example. A permeation-enhanced transdermal gel, ZYN002 is targeting the developmental genetic condition known as Fragile X syndrome (orphan drug designation obtained), as well as focal seizures and osteoarthritis. The company is also advancing a pro-drug of THC called ZYN001 for fibromyalgia and peripheral neuropathic pain. The company cites clinical data suggesting that THC and CBD have a high therapeutic index with low toxicity in support of its development pipeline’s potential (http://nnw.fm/LoQH1). It is intriguing to imagine a future where biosynthesis technology bridges the gap between the benefits of natural plant extracts and laboratory-manufactured, pharmaceutically produced cannabinoid variants.

Cara Therapeutics (NASDAQ: CARA) is a clinical-stage biotech focused on developing and commercializing new chemical entities for the management of acute pain, chronic pain and pruritus (itch). The company’s approach is to develop new products that selectively target the body’s peripheral kappa opioid receptors. Cara is developing a novel and proprietary class of product candidates that target the body’s peripheral nervous system and have demonstrated initial efficacy in patients with moderate-to-severe pain and pruritus without inducing many of the undesirable side effects typically associated with currently available pain and itch therapeutics. The company’s most advanced compound, CR845, is currently undergoing clinical testing. As reported on the company’s website, results from multiple randomized, double-blind, placebo-controlled phase 2 trials in patients undergoing laparoscopic hysterectomy or bunionectomy procedures, show that I.V. CR845 treatment resulted in statistically significant reductions in both pain intensity and opioid-related side effects.

Axim Biotechnologies (OTCQB: AXIM) focuses on the research, development and production of cannabis-based pharmaceutical, nutraceutical and cosmetic products. The company’s line of flagship products include CanChew+®, a CBD-based controlled release chewing gum; CanChew+ 50®, which contains 50 mg of CBD and is undergoing clinical trials in patients with irritable bowel syndrome (“IBS”); and MedChew Rx®, a combination CBD/THC gum that will undergo clinical trials for the treatment of pain and spasticity associated with multiple sclerosis. AXIM has several products developed or in developmental stage for treatment and/ or prevention of multiple conditions and symptoms. Axim is precisely the kind of multi-front developer which could benefit mightily from InMed’s biosynthesis technology.

The mounting need to find effective, non-addictive alternatives to existing medications like opioids for treating chronic and severe pain will continue to draw attention to trailblazers such as InMed. The potential of cannabinoid-based therapies, which lack the crippling and even deadly side effects of opioids, is only starting to be properly understood when it comes to addressing these objectives. The ability to produce large quantities of otherwise not commercially viable cannabinoids for select combination therapies that can be administered topically is quite possibly the most disruptive development yet witnessed in the still-young cannabinoid therapy space.

Thus, a company like InMed, with an attractive pipeline under development and proprietary biosynthesis technology it can exploit or even license out, is one for investors to keep an eye on.

For more information on InMed Pharmaceuticals, please visit: InMed Pharmaceuticals, Inc. (CSE: IN) (OTCQB: IMLFF).
The QualityStocks Daily Newsletter http://Newsletter.QualityStocks.net

The QualityStocks Daily Blogs http://Blog.QualityStocks.net

Please read FULL Compensation Disclosures and other disclaimers at http://www.qualitystocks.net/disclaimer.php
QualityStocks
Site Admin
 
Posts: 1123
Joined: Mon May 21, 2007 7:58 pm
Location: Scottsdale, AZ

Previous

Return to QualityStocks Featured Companies

Who is online

Users browsing this forum: No registered users and 1 guest